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The detoxification pathway in the liver is the vital pathway for detoxifying 
xenobiotics and endogenous molecules in all vertebrates. The majority of 
molecules require three phases for detoxification, phase I preparation, phase II 
conjugation and phase III excretion. Research to date demonstrates how 
human gene polymorphisms and lifestyle factors may alter the fate of the 
molecule. Additionally, research to date indicates that genotyping can be useful 
for personalised medicine before administering a drug, the information is used 
to inform the patient which drug can be or cannot be used for treatment. This is 
to prevent adverse toxicological reactions during treatment of a disease. 
Therefore, monitoring the fate of glucuronides in relation to diseases, should 
have invaluable potential in detection of relevant diseases at earlier stages.  
The glucuronide species may reflect disease causation influences by genetics 
and non-genetic factors. For instance, in disease influenced by lifestyle factors, 
the glucuronides may include glucuronides that have been produced from 
xenobiotic molecules that have been through glucuronidation. Since research 
have not addressed the relation of the fate of glucuronide species and diseases. 
It is important to clarify the concept for disease prognostics based on 
glucuronide species in their excretion. Therefore, the aim of the research is to 
explore the potential application of glucuronides for disease prognosis and 
disease, by revealing the relationship between glucuronides and disease. The 
research presented in the thesis demonstrate that glucuronide species are 
potentially associated with diseases. For instance, to date, in prostate cancer 
three glucuronides are associated with the disease: androsterone glucuronide 
(ADT-g), androstane-3α, 17β-diol glucuronide (3α-diol-G), and androstane-3a, 
17b-diol-17 glucuronide (3α-diol-17G), when prostate cancer is influenced by 
gene variants. In type 2 diabetes, influenced by lifestyle, three glucuronides are 
associated with the disease: 2-phenylethanol glucuronide, deoxycholic acid 3-
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1.1 Glucuronides as a biomarker for disease 
Biomarkers are molecules that can be used as a measurable indicator to 
determine the presence of a disease or biomarkers can be used to identify 
disease severity (Law et al. 1995; Rodriguez et al. 1997; Colomer et al. 2000). 
The criteria that makes a good biomarker include: the biomarker must be 
present in peripheral blood and or/bodily fluids (such as blood, urine or salvia) 
(Takahashi et al. 2000; Wurst et al. 2000; Warankulsuriya et al. 2000), easily 
detectable for quantification (An et al. 2000), robust (Leonardi et al. 2001), 
associated to a clinical condition (Bhatavdekar et al. 2000), and cost effective 
(Henriksson et al. 2010). Therefore, in order for glucuronides to be a good 
biomarker, glucuronide molecules need to fit the criteria. 
 
The application of glucuronides as a biomarker for diagnostics and prognostics, 
glucuronide molecules must meet the specified criteria to be considered as a 
good biomarker for disease. Thus, research to date demonstrates that 
glucuronides can be detected in peripheral blood (Wang et al. 2004), urine (Lutz 
et al. 2006), and saliva (Qi et al. 2002). Furthermore, glucuronides can easily be 
quantified (Annesley and Clayton 2005). Research to date does not reveal if 
glucuronide molecules are robust as a disease biomarker. Lastly, glucuronides 
could be associated to clinical conditions (Lévesque et al. 2014; Johnson et al. 
2016; Zhao et al. 2017) and refer to Aim and Objectives. Research to date does 
discuss or evaluate the cost-effectiveness for glucuronides as a biomarker. 
According to the research to date, this demonstrates that glucuronides could be 
a good biomarker for disease diagnostics and prognostics. However, further 
research is required to explore the cost-effectiveness and the robustness of 
glucuronides as a biomarker for disease. 
 
1.2 Overview of detoxification pathways 
The human detoxification pathway is the vital pathway in the liver for the 
detoxification of xenobiotics and endogenous molecules (Bosma et al. 1994; 
Pacifici et al. 1997; Stillwell et al. 1997; Dietrich et al. 2004). The molecules 
which can be detoxified include xenobiotics pollutants Turteltaub et al. (1990); 




1996; Turan et al. 2001; Yamamoto et al. 2008; Tomasi et al. 2010), illicit drugs 
(Vitcheva and Mitcheva 2007; Meyer et al. 2008; Bunten et al. 2010), food 
additives (Yu et al. 1997; Dreiseitel et al. 2008; Mozrzymas et al. 2017), and 
endogenous molecules (Schmid et al. 1957; Hong et al. 2004; Park et al. 2006). 
These pathway serves to reduce the toxicity effects of the molecules by 
changing the structure of the molecule by the addition of glucuronic acid to a 
molecule, changing the charge of the molecule, becoming water soluble. 
However, some molecules do not undergo three phases, the three phases have 
been discussed below. For the detoxification of molecules (van der Deure et al. 
2008; van de Steeg et al. 2012; Kotsampasakou et al. 2015), organic anion 
transporters (OATs), transports transport molecules into the cell for 
detoxification such as OATP1B1 transporting bilirubin into the liver. An overview 
discussion of OATs has been presented in Appendix 4 Section A4 1.0. Below 
discusses a generalised explanation of the detoxification pathway. 
 
Phase I is mediated by cytochrome P450s (CYP450s), known as the 
“preparation” phase in the detoxification pathway, preparing molecules by 
different biochemical reactions (Slaughter and Edwards 1995; Huan et al. 1998; 
Meyer et al. 2001), oxidations, reductions or hydrolysis. These reactions expose 
or introduce a functional group: hydroxyls (-OH) (Figure 1.1), thiol (sulfhydryl) (-
SH), amino groups (-NH2) or carboxylic acids (-COOH) (Williams 1967; 
Williams 1972; Schwartzman et al. 1987; Boon et al. 1997; McKinney et al. 
2004; Butler et al. 2013; Ashrap et al. 2017; Sang et al. 2018), for phase II 
conjugation (Sun et al. 2012;; Alkharfy et al. 2013;  Zhu et al. 2015), in most 
cases. Irinotecan for example (Figure 1.1), the inactive metabolites does 
 not require glucuronidation. CYP450s contain a heme group which aids the 
binding of molecules to the protein active site, classifying CYP450s as heme-
thiolate proteins (Ohno et al. 2000; Auclair et al. 2001). Essentially, phase I is 
the preparation of molecules exposing the functional groups for phase II 
conjugation via glucuronidation by Urine Diphosphate (UDP)-
glucuronosyltransferase (UGT)  and other phase II conjugation reactions 












Figure 1.1: Examples of phase I detoxification. A) Ibuprofen is hydroxylated by 
CYP3A4 to produce the metabolite 2-OH-ibuprofein (Chang et al. 2008). B)  Irinotecan 
is oxidised by CYP3A4 which synthesises two inactive metabolites, APC and NPC.  
 
Phase II is the conjugation phase which detoxifies a majority of molecules, by 
conjugating molecules to the functional group for detoxification. Conjugation 
may include: sulphation that attaches sulfhydryl (thiol) (-SH) groups (Sharer et 
al. 1995), glucuronidation (attachment of glucuronate, UDP-GA), (Iyer et al. 
1998), acetylation that attaches acetyl groups (CH3CO) (Windmill et al. 2000), 
and glutathione conjugation which conjugates glutathione (GSH) molecules 
(Buratti et al. 2015). Glucuronidation is the major phase II conjugation process 
due to the unlimited availability of glucose (discussed further in Section 8.0). In 
glucuronidation, UGTs conjugate urine diphosphate glucuronate (glucuronic 
acid, UDP-GA) to the introduced or exposed functional group on the molecule, 
synthesising a glucuronide (Figure 1.2). Molecules become detoxified by 
glucuronidation due to the addition of glucuronate to a hydrophobic molecule, 
increasing water solubility and the polarity of a molecule (Kang et al. 1995; 













Figure 1.2: Examples of phase II conjugation reactions. A) 2-OH-Iburprofen is 
conjugated to UDP-GA for glucuronidation by UGT2B7 (Sakaguchi et al, 2004). B) 
Testosterone can be sulphated in phase II detoxification by SULT1A1 and SULT2A1 
(Schulze et al. 2013). C) Glutathione conjugation of acetaminophen by GSTT1, GSTP1 
or GSTM1 for phase II detoxification, by which glutathione is conjugated to 
acetaminophen.  
 
Phase III known as the “excretion” phase, requiring transporters for the 
elimination of phase I and II products. These transporters are mainly ATP 
binding cassette (ABC) transporters, for example multidrug resistance 
transporters such as MDR1 (Radosevich et al. 1989; Valverde et al. 1992; Kim 
et al. 1996). ABC transporters situated on cell membranes, efflux phase I and II 
metabolites from the cell (Wang et al. 2008; Pohl et al. 2011; Song et al. 2014; 
Crow et al. 2017; Aguiar et al. 2019). Once out of cells phase I and II products, 
enter the bile duct and into the small intestines or the urinary tract.  
 
ABC transporters use active transport, requiring hydrolysis of ATP to ADP for 
molecule transportation (George and Jones 2013; Karasik et al. 2017). ABC 
transporters are expressed on the blood brain barrier (BBB), on the apical 
surface of a cell membrane (Carl et al. 2010; Bakhsheshian et al. 2013; Chapy 
et al. 2015; Liu et al. 2018). The presence of ABC transporters on the BBB, 
prevents endogenous and xenobiotic molecules from entering the brain and 
induce a toxicological effect. (Shumacher et al. 2012; Disdier et al. 2015; 
DisMøllgård et al. 2017). Additionally, ABC transporters are expressed on the 




Ogasawra et al. 2010; Perdomo et al. 2013; Kis et al. 2016; Sawangrat et al. 
2018). Transporters expressed on the intestinal barrier, efflux phase I and II 
metabolites into the bile or urine for elimination. The molecular mechanism for 
molecule transport are discussed below. 
 
ABC transporters, use a mechanism of active transport, facilitated by ATP 
hydrolysis, using nucleotide-binding domains 1 and 2 (Hou et al. 2001; Berger 
et al. 2005; Scott-Ward et al. 2007; Kloch et al. 2010; Nagao et al. 2012; 
Corradi et al. 2015; Urbatsch et al. 2018). These research articles postulated 
NBD1 is utilised for ATP hydrolysis whilst, NBD2 is associated with the opening 
of the transporter. Additionally, Figure 1.3 presents a theoretical model of the 
ATP switch model (proposed by Higgins and Linton 2004). It is not yet clear 
whether ATP hydrolysis and opening of the transporter occurs synergistically or 
alternatively.   
Figure 1.3: ATP switch model of ABC transporters. Step I) molecule (green oval) 
enters the transporter. Step II) the transporter closes and the NBDs dimerise, with ATP 
(yellow circles), binding to the nucleotide binding domains. After closure, the 
transporter rotates to release the molecule. Step III) ATP is hydrolysed to ADP. Step 
IV) ADP is released from the NBDs (Higgins and Linton 2004).   
 
Furthermore, ABC transporters are subjected to phosphorylation by protein 
kinase A (PKA) or protein kinase C (PKC). PKAs and PKCs phosphorylate the 
ABCA and ABCB family of transporters (See et al. 2002; Roosbeek et al. 2004; 
Nandi et al. 2008),  and the ABCC family of transporters (Chambers et al. 1990; 
Chambers et al. 1992; Chambers et al. 1994; Sachs et al. 1996). Thus if a 
transporter is phosphorylated by PKC in a disease, an accumulation of toxic 
molecules may occur, allowing the disease to develop. Alternatively, increased 
expression of a ABC transporter could be a contributing factor in chemo-





All potential phosphorylation sites have been presented in Appendix 4 Table 1. 
Collectively, phosphorylation by PKA induced increased expression of the 
transporters. Conversely, phosphorylation by PKC induces internalisation, 
reducing transport activity. 
 
Organic anion transporters (OATs) excrete anionic molecules from the body. 
OATs are predominantly expressed within the renal tubes of the kidney (Eraly et 
al. 2005) and the liver (Rost et al. 2005). Eraly et al. (2005) reported that in 
OAT1 knock-out mice, the transport of para-aminohippuric acid (PAH) was 
reduced. In a later study, Bulacio et al. (2015), reported that when cisplatin 
(chemotherapy drug for cancer), that is known to induce acute kidney injury 
(AKI), increasing OAT5 expression. Furthermore, when N-acetylcysteine is co-
administered with cisplatin, the expression of OAT5 returns back to basal 
expression. Therefore, this clearly demonstrates that OATs also transport 
molecules for elimination from the body.  
 
 
1.2.1 Glucuronide as carbon source for Escherichia coli  
E. coli residing in the large intestine and urinary tract scavenge glucuronides as 
a carbon-based nutrient source (Liang et al. 2005). The gus operon (Jefferson 
et al. 1986; Liang et al. 2005), expresses glucuronidase by the gene known as 
gusA (uidA), which cleaves glucuronides into glycones (nutrients) and 
aglycones (toxic molecules), the latter that is excreted. In the gus operon 
system there is also a gusR gene coding for the repressor protein. GusR 
suppresses transcription when glucuronides are not present. In the presence of 
glucuronides (Figure 1.4), GusB transports glucuronides across membranes 
from outside of the cell and into the cytoplasm. There is evidence to show that 
GusC enhances glucuronide transport into E. coli, but detailed molecular 
mechanisms remains obscure (Liang et al. 2005).  However, the specific 
molecular function of GusC remains unclear but, it is thought that GusC is a 




across the outer membrane (Nakae 1976). Further studies are required to 





Figure 1.4: The gus operon system in E. coli. Adopted from the research of 
(Jefferson et al. 1986; Liang et al. 2005). If the glucuronides produced in a disease do 
not reflect  abnormalities, the aglycone component of glucuronides could be used for 
disease diagnostics.  
Aglycones released from E. coli are either eliminated from the human body or 
they enter the enterohepatic circulation (Figure 1.5). In the enterohepatic 
circulatory system, aglycones are “reabsorbed” back into the bloodstream by 
passive diffusion, through the large intestine. Once in the bloodstream, an 
aglycone enters back into the liver (Samuel et al. 1968; Kent et al. 1972; Walsh 
and Levien 1975; Inoue et al. 1979; Blumenthal et al. 1980). Once aglycones 
enter the liver, they are detoxified via glucuronidation, again by the 
enterohepatic circulation system (Figure 1.5). Enterohepatic circulation occurs if 


















Figure 1.5: Enterohepatic circulation (Adopted from: Wilson et al. 1992, p. 9). Used 
with the permission from Elsevier. Copyright © 1992 ACADEMIC PRESS, INC. 
Published by Elsevier Inc. All rights reserved.  
 
1.3 Influences of genetic variation on glucuronide production 
The three phases of the detoxification pathway can be affected by genetic 
variation which can result in abnormalities and alterations, in the detoxification 
of molecules by different molecular mechanisms (Spencer et al. 2006; Balin and 
Cascalho 2010), as discussed below. From here on in, for Section 1.3 and 1.4, 
they will discuss how genetic variation influence molecule detoxification and 
likewise for epigenetic regulation.   
 
Genetic variation accounts for the differences between individuals. Genetic 
variation within a population is influenced by three factors: mutation (Lai et al. 
2019), gene flow (Botigué et al. 2013) and genetic shuffling (Star and Spencer 
2013). In human somatic cells, the rate of mutation has been reported to be 
approximately 10-10 per base pair (bp), per cellular generation (Balin and 
Cascalho 2010; Gurskaya et al. 2012). Whilst in germline cells, the rate of 
mutation has been reported to be approximately 1.2 x 10−8 (Milholland et al. 




rate of mutation occurs for every 2,200 to 2,800 bps (Hodis et al. 2013; 
Jayaraman et al. 2014; Hao et al. 2016). However, DNA can be repaired by 
several repair mechanisms. In germline cells, DNA can be repaired by any of 
the following: nucleotide excision repair (NER) (Jansen et al. 2001), base 
excision repair (BER) (Olsen et al. 2001), mismatch repair (MMR) (Velasco et 
al. 2004) or, DNA double strand break repair (DSBR) (Allard and Colaiácovo 
2010). In somatic cells non-homologous end joining (NHEJ) (Felgentreff et al. 
2014), occurs for DNA repair.  
 
1.3.1 Gene flow and genetic shuffling  
Gene flow alters gene frequencies within a population via vertical gene transfer, 
transferring genes from parent to offspring (Lee et al. 2015). Vertical gene flow 
can be influenced by genetic shuffling and may also alter the integrity of a gene. 
The difference of gene flow compared to genetic shuffling is that gene flow, is 
associated with the movements of a gene from one generation to another (Lee 
et al. 2015). Genetic shuffling leads to the production of different traits (Spencer 
et al. 2006), as discussed below.  
 
Genetic shuffling is caused by DNA recombination, leading to genetic mutation 
or potential newly formed genes. DNA recombination can be interpreted as an 
exchange of DNA strands which synthesise new DNA sequences (Spencer et 
al. 2006; Vanhooff et al. 2009; Qi et al. 2015). This is often observed at regions 
where DNA has been broken, a chance for re-joining to another DNA sequence. 
DNA recombination can therefore, strongly influence genetic variations. Thus it 
is logical to believe that these genetic events could also induce alterations in the 
glucuronidation of molecules. 
 
1.3.2 Alternative splicing  
Genetic variations can be caused by alternative splicing (AS) (Li et al. 2016) 
and sometimes known as exon skipping. In exon skipping, an exon skipped or 
spliced out of the pre-mRNA transcript (Gurskaya et al. 2012; Cui et al. 2017). 
AS patterns could disrupt the frameshift of the coding region, promoting protein 




skipping alone can influence a range of conditions for example: cystic fibrosis 
(Pagani et al. 2000; Pagani et al. 2003; Pagani et al. 2005; Aznarez et al. 2007) 
and neuromuscular diseases (Incitti et al. 2010; Dick et al. 2013; Barthelme et 
al. 2015). Exon skipping can also be observed in other conditions such as 
cancer (Kahles et al. 2018; Wang et al. 2019). Therefore, in diseases such as 
cancers, AS could be a target for therapeutic applications for disease treatment.  
 
Genetic variation can be tested currently through two common methods, gene 
mapping (Fledel-Alon et al. 2013) and DNA sequencing (Choudhary et al. 
2017). These methods determine all potential variants that may be present, 
driving personalised medicine (PM). PM has more beneficial effects to a specific 
patient compared to standard treatment methods (Horgan et al. 2014; Minsker 
et al. 2016). This is because PM is tailored to a specific patient, thereby the 
treatments provided to a patient, is more effective.   
 
AS patterns have be observed in the detoxification pathway, within phase II 
glucuronidation. Rouleau et al. (2013) reported two UGT1A isoforms, i1s and 
i2s (truncated). The study reported that the i2s negatively regulates i1s via 
protein-protein interactions. Rouleau et al. (2013) reported that the  i2s variant 
had less sensitivity towards drug-induced cellular death. The study identified 
that the production of reactive oxygen species (ROS) were reduced and 
increased expression of superoxide dismutase 1. Later, Labriet et al (2018) 
reported “intronisation” (the conversion of exons to introns) of exon 1-2 and 
exon skipping of exons 4-6 of UGT2B10 which are human specific. It is believed 
that these AS patterns on xenobiotics and endogenous molecule 
glucuronidation could be altered but further research is required. Reduced 
function of the glucuronosyltransferase genes such as the UGT2B, may lead to 
certain chronic diseases such as having the UGT2B17 gene deleted from the 
genome (See Section 5.2.3). Therefore, AS could be a subject for 





1.4 Epigenetics  
Epigenetics defines molecular processes which regulates gene expression, by 
acting upon DNA, without causing a mutation to a DNA sequence of a gene 
(Waddington 2012). There four common epigenetic regulatory processes have 
been discussed below: DNA methylation, histone modifications, ubiquitination 
and microRNAs. 
 
1.4.1 DNA methylation 
DNA methylation is a regulatory cellular process affecting gene expression 
(Panning and Jaenisch 1996; Danam et al. 1999; Fuks et al 2002). DNA 
methylation regulates gene expression through “silencing” the gene. Gene 
“silencing” happens by the attachment of methyl groups (CH3) to cytosine and 
guanine rich regions (CpG islands) in a gene promoter. DNA methylation is 
catalysed by DNA methyltransferases (DNMTs). DNMT1 is expressed on 
chromosome 19p3.2, DNMT2 is located at chromosome 5 and DNMT3A is 
located at 2p23.3 whilst, DNMT3A is located at 2p23.2 and DMNT3B is located 
at chromosome 20q11.21, in humans. Gene silencing occurs since RNA 
polymerase cannot recognise methyl groups attached by a DNMT. 
Consequently, transcription is suppressed (Palacios et al. 2010; Hu et al. 2013; 
Bechis et al. 2015; Hong et al. 2017), thereby gene silencing occurs.  DNA 
methylation is also a heritable trait, for at least three generations.  
 
UGT1A1*28 is an extensively studied variant of UGT1A1 due to the association 
of Gilbert’s syndrome (a condition where an individual have increased 
unconjugated bilirubin concentrations, Section 6.1.2) and bilirubin 
glucuronidation. UGT1A1*28 has reduced expression due to an insertion within 
the gene promotor. Epigenetic regulation of the UGT1A1*28 has been reported 
by Bélanger et al. (2010), they reported that methylation of UGT1A1 within the 
5’-flanking region at CpG -4 region negatively regulates UGT1A1 expression 
(Figure 1.6). A later study by Yasar et al. (2013), confirms this and reported that 
the transcription factor response element (USF) (-4 region) of UGT1A1*28 is 












Figure 1.6: Differences between of the USF region of UGT1A1 and UGT1A1*28. 
The orange region presents the -4 USF region of the UGT1A1 gene. The markers on 
UGT1A1*28 represent the methylation markers on the USF region. 
 
1.4.2 Histone acetylation and phosphorylation  
Histones are positively charged proteins that are rich with the histidine amino 
acid (Hildebrand et al. 1977; Paponov et al. 1980; Righetti et al. 1983). The 
function of histones allows the condensation of DNA to chromatin. Histones are 
subjected to epigenetic regulation by acetylation and phosphorylation, 
discussed below.  
 
Histone acetylation is the addition of acetyl groups (COCH3) onto lysine 
residues at histone 3 (H3) and 4 (H4) (Figure 1.7). The addition of acetyl groups 
neutralises the positive charge, relaxing H3 and H4, enhancing gene 
transcription (Kato et al. 2007; Chen et al. 2010; Dagdemir et al. 2013; Verdone 
et al. 2015; Nicolas et al. 2018). Furthermore, histone phosphorylation 
contributes to cell division for chromosome condensation and segregation (Wei 
et al. 1999; Ota et al. 2002; Huang et al. 2006; Wilkins et al. 2013; Kruitwagen 
et al. 2015). In addition there are other mechanisms such as DNA reparation 













Figure 1.7: Lysine acetylation on histone 3 and histone 4. Partial protein 
sequences of histone 3 and histone 4 protein have been used. The markers at the 
lysine (L) residues present acetylation markers. Histone 3 UNIPROT ID: P68431. 
Histone 4 UNIPROT ID: P62805.  
 
However, to date there is not any research which discusses histone acetylation 
and phase II glucuronidation. Clearly, further research is needed to reveal 
whether histone acetylation and phosphorylation the role in influencing UGT 
expression and in turn, the effects on molecule glucuronidation.  
 
1.4.3 Ubiquitination  
Ubiquitination is associated with “marking” proteins for degradation (Nguyen et 
al 2013; Maurer et al. 2016). Proteins marked for degradation have ubiquitin 
protein chains attached onto lysine residues, acting as a marker for a 
proteasome (Fletcher et al. 2015; Wu et al. 2018). The marked protein for 
degradation is recognised by a protease and subsequently degraded. A 
common example is p53 degradation by mouse double minute 2 homolog 
protein (MDM2), an E3 ubiquitin protein (Pichiorri et a. 2010; Sparks et al. 2014; 
Zhu et al. 2018). Thus, the degradation of p53 could be also be a potential 
disease causing factor for cancer.   
 
The effects of ubiquitination on glucuronosyltransferases have not been 
explored. This does not necessarily imply that ubiquitination does not affect 
glucuronosyltransferase proteins. Therefore, it is important that this concept is 
explored to understand the potential impacts ubiquitination has on molecule 






microRNAs (miRNAs) represent another epigenetic factor, regulating gene 
expression. miRNAs are non-coding RNAs which are approximately 22 
nucleotides long (Ebhardt et al. 2010; Fang et al. 2013; Rolle et al. 2016). miRs 
regulate gene expression by targeting messenger (m)RNA transcripts for 
degradation causing gene “silencing” (Zeng et al. 2003; Wu et al. 2006; 
Hausser et al. 2009; Helfer et al. 2012; Antic et al. 2015; Freimer and Blelloch 
2018). mRNA degradation occurs in two ways, the first involves the binding of 
miRNAs to the 3’ untranslated region (UTR) (A/U rich regions of the 3’ UTR). 
Alternatively, the polyadenylation region on mRNA transcripts can be removed 
(Wu et al. 2006; Beilharz et al. 2009). miRs regulate the expression of different 
UGTs by binding to different regions of a UGT which has been reported in a 
number of studies (Table 1.1), that the miRs regulate gene expression. 
 
Table 1.1: Some reported miRNAs which regulate some UGT expression 
miR UGT gene Predicted 
binding position 
if reported 
























+656 to +677  
Suppression  miR-141-3p +52 to +76 
miR-22a-3p +54 to +76 
miR-135a-5p  
UGT2B4 












miR-3664-3p UGT2B7  




miR-216b-5p UGT2B10 Not reported Reduced  (Dluzen et al. 
2016) 




et al. 2018) 
miR-376c UGT2B17 3’-UTR Reduced 
expression 
(Wijayakumara 
et al. 2015) 
 
The evidence presented in Table 1.1 shows that miRNAs negatively regulate 
UGT expression. Therefore, the negative regulation in UGT expression could 
contribute to the accumulation in the number of toxic molecules within the 




the development of diseases. Additionally, this leads to the suggestion that in 
despite of gene variants that act as a predisposition for diseases, gene variants 
may not necessarily be the sole cause of disease.  
 
1.4.5 Epigenetics and disease 
The previous sections, Section 1.3.1 to 1.3.4 discusses different epigenetic 
regulatory mechanisms for gene expression. In prostate cancers for example 
research has reported hypermethylation patterns of GSTP1 with 
hypermethylation (Prior et al. 2010; Chen et al. 2013; Martignano et al. 2016; 
O’Reilly et al. 2019). Thus, the expression of GSTP1 is non-existent and 
consequently the suppression of GTSP1 could contribute to the accumulation of 
toxic molecules and metabolites. The accumulation of toxic molecules in the 
prostate could therefore contribute to the severity of prostate cancer.  
Ubiquitination in prostate cancers has also been reported (Guan et al. 2008; 
Chang et al. 2012; Wang et al. 2016; Ma et al. 2018). Tumour necrosis factor 
(TNF)-receptor associated factor 4 (TRAF4) has E3 ligase functional 
mechanisms (Kim et al. 2017; Diao et al. 2018), degrading proteins that have 
been marked for degradation. Singh et al. (2018) reported that in prostate 
cancer TRAF4 degrades Tropomyosin receptor kinase A (TrkA), by which TrkA 
regulates prostate cancer metastasis. The ubiquitination of TrkA by TRAF4 
promotes prostate cancer metastasis. However, histone modification by 
acetylation and phosphorylation has not been reported thus far. miRNAs also 
influence prostate cancer and severity. One particular miR, miR-141 has been 
associated with prostate cancer. Richardson et al. (2019) reported that when 
miR-141 is highly expressed, biochemical recurrence of prostate cancer 
happens. Furthermore, the expression of miR-145 is thought to contribute to the 
aggressiveness of prostate cancer. It is recommended that further studies 
should be conducted to elucidate whether gene expression in prostate cancer is 






The detoxification pathway is important for human health. The detoxification of 
molecules may vary in different individuals influenced by ethnicity 
(Premawardhena et al. 2003; et al. 2004; Westlind-Johansson et al. 2006; Zhou 
et al. 2009; Santos et al. 2014; Court et al. 2017). Both genetic and non-genetic 
factors could affect the detoxification of molecules leading to diseases. Thus, 
the presence of a disease may correspond to abnormalities in altered 
glucuronide production which could be used to reveal a glucuronide spectrum. 
The different glucuronide spectrum could therefore be used for disease 
prognosis and diagnosis. Therefore, finding or clarifying this association of the 
altered glucuronide spectrum with certain disease is of interest of this research. 
1.6 Aim and Objectives  
The aim of this research was to clarify the association of glucuronides for 
disease prognosis.  
To ensure the aim was achieved the following objectives were outlined: 
1. Evaluate how genetics affect the detoxification pathway 
2. Evaluate lifestyle factors which may affect the detoxification pathway 
3. Evaluation of published gene polymorphic frequencies on relevant genes 
from different human ethnicities, using bioinformatic tools, databases, 
and published peer-reviewed research. 
4. Reveal potential glucuronide spectrums reflecting objectives 1 and 2. 
5. Postulate the potential of clinical applications of the research.  
1.7 Thesis structure 
To ensure the aim and objectives are successfully achieved multiple chapters 
have been presented in this thesis. Below provides an outline of the different 
chapters within the thesis. 
 
Chapter 1: Introduction. 
Chapter 2: The Metabolic Fate of Different Medicinal Drugs. 
Chapter 3: The Metabolic Fate of Different Illicit Drugs. 
Chapter 4: The Metabolic Fate of Different Food Additives. 




Chapter 6: The Metabolomic Fate of Different Xenobiotics. 
Chapter 7: The Potential Application of Glucuronides for Disease Prognostics. 
























































































2.1 Method for databases 
The method undertaken involved evaluating data in research to date. Journal 
databases were used to obtain relevant literature: Google Scholar, Web of 
Science, PubMed and Scopus (Table 2.1). Bioinformatic databases and tools 
including: OMIM, NCBI, gnomAD and Exome Aggregation Consortium (ExAC) 
(Table 2.1) were used to access allele frequencies for different human 
ethnicities and research to date was used.  
 
Table 2.1: Databases used for the research  
Database Database URL Reference (if possible) 
Google 
Scholar 








PubMed https://pubmed.ncbi.nlm.nih.gov/ Not applicable 
NCBI https://www.ncbi.nlm.nih.gov/ Not applicable 
OMIM https://www.omim.org/ (Amberger et al. 2015; 
Amberger et al. 2019) 





Database no longer available: refer to: 
https://gnomad.broadinstitute.org/ 
ExAC:(Lek et al. 2016) 
 
gnomAD:(Karczewski et al. 
2019) 
Ensembl https://www.ensembl.org/index.html (Hunt et al. 2018) 
ClinVar https://www.ncbi.nlm.nih.gov/clinvar/ (Landrum and Kattman 2018) 
 
Online Mendelian Inheritance in Man (OMIM) is a database which report genes 
and their function and gene variants associated to a disease (Amberger et al. 
2019). OMIM was used for one particular disease, phenylketonuria (PKU) 
(OMIM%21600) discussed in Chapter 4. This was to gain a further 
understanding of how the disease is caused at the molecular level, since 
aspartame is metabolised by phenylalanine hydroxylase (Fusetti et al. 1998). 
From the information provided by OMIM in relation to PKU, a further search was 
taken using google for the discussion of aspartame and the relation to disease 
as discussed in Section 4.1. The use of Web of Science, PubMed and google 
scholar is discussed in Section 2.3. Additionally, OMIM was used to explore 





gnomAD and ExAC are bioinformatic databases that report allele frequencies of 
gene variants, homozygous and heterozygous, within a specific population or 
ethnic group (Lek et al. 2016; Karczewski et al. 2019). Both gnomAD and ExAC, 
along with published peer-reviewed research on human population genetics 
was used to demonstrate which ethnicities, had the variant as evident in 
Chapters 3 to 7. This is because one ethnicity will be at a higher risk of a 
disease compared to another population or ethnicity. For instance, prostate 
cancer occurs more frequently in black men compared to white men and Asian 
men, in England alone (Lloyd et al 2015). Thus, treatment could be prioritised 
for individuals who are at a higher risk of a disease, compared to another 
individual.     
 
Ensembl is a bioinformatic database that provides such as information on a 
gene and reporting variant(s) of a gene population genetics of a gene variant 
and the association to disease (Hunt et al. 2018). Additionally, Ensembl 
provides a genome browser which can be used to analyse a particular area of 
the human genome (Hunt et al. 2018). Ensembl was used to explore population 
genetics of a gene variant and to explore an association of a variant to a 
disease, using a variant ID (rs#) or the gene variant annotation such as 
CYP2D6*4 .    
 
ClinVar is an archive bioinformatic database which contains gene variants and 
the relationship of a gene variant (intergenic, exon or a gene from mitochondria 
to a disease (Landrum and Kattman 2018). ClinVar was used to help associate 
gene variants discussed in this research, to a disease along published peer-
reviewed research using PubMed and google scholar.  
 
2.2 Workflow of bioinformatic and genetic analysis 
Below presents a workflow diagram of the process undertaken. An explanation 
of each database and the purpose why each database has been used is 





Figure 2.1: Workflow of the bioinformatics method undertaken.  
 
2.3 Method for Chapter 8 
To collect the results that have been presented in Chapter 8, three journal 
databases were used, Google Scholar, Web of Science and PubMed. Using the 
three journal article databases, search terms were applied to retrieve all the 
papers for analysis, which may report glucuronides associated to a disease 
(type 2 diabetes mellitus, colorectal cancer, prostate cancer, breast cancer, liver 
cancer, and Parkinson’s disease). Figure 2.1 presents a flow diagram of the 
process undertaken for Chapter 8. Once all the papers were collected, all the 
papers were analysed using inclusion and exclusion criteria (Table 2.2 and 
Figure 2.2), in accordance to the PRISMA recommended guidelines for 
systematic reviews (Moher et al 2012). The inclusion and exclusion criteria have 
been designed to retrieve journal articles that have reported glucuronides 
associated to a disease.   
 
Google search of 
"molecule name and 
gene associated to the 
detoxification pathway". 
Google search of 
"molecule and gene and 
gene variant" 
Gene varaint searched 
in OMIM, Ensembl, 
ClinVar, and published 
peer review research. 
Gene variant ID (rs#) or 
gene variant annotation 
was used.  
Allele frequencies of a 
gene variant was 
searched on OMIM, 
Ensembl, ExAC, and 
published peer 
reviewed research 
using PubMed and 
Google Scholar and 
reported upon. 
Search was taken to 
reveal if a gene variant 
had a association to 
disease. Search was 
taken on OMIM, 
Ensembl, ClinVar, and 
published peer reviewed 
research from PubMed 
and Google Scholar.  
Discussion of each 
molecule and 
detoxifixation discussed 
between Chapters 3 and 
6. The consequence of 
the variant on molecule 
detoxification has been 
discussed, with allele 
frequencies, and variant 





















Search terms: Disease name 
AND glucuronide AND genetic 
polymorphism/lifestyle 
Search terms applied to: 
Scopus, Web of Science, 
NCBI PubMed and Google 
Scholar 
Retrieved all papers   
Paper analysis for 
glucuronides 





Table 2.2: Inclusion and exclusion criteria for journal article analysis 
 
Part Description Inclusion criteria Exclusion criteria 
1 Journal title 
analysis 
Keywords (at least one): 
glucuronides, disease, gene 
polymorphisms or lifestyle related 
factors, human sample.  
 
 
Duplicate studies by 







2 Abstract analysis Glucuronide(s) 
detected/biomarker(s)/metabolites  
 
Human sample analysis 
 
Disease influenced by gene 







Samples which do not 





Disease not specified  
 
No abstract provided 
3 Full paper 
analysis 
Analysis using human samples  
 
 
Glucuronides associated to a 
disease 
 
Glucuronide detection from 
individuals who have a disease 
caused by both gene 





only (full text not 
available)  
 









Papers that are not 
available in English 
 
Glucuronides which 
are reported that are 
not associated to a 
disease. 
 
Glucuronides that do 















































Total number of 




Part 1 exclusion: 









Keyword(s) not mentioned: 
n=1 






Total number of 




Total number of 





Part 2 abstract exclusion:  
Glucuronides not reported: 
n= 51 
 
Disease not specified: n=9 
 
Abstract not provided: n=0 
 
Animal models: n=0 
 
Animal studies: n=1 
Part 3 exclusion  






Glucuronides reported that are 
not associated to a disease and 
unreported: n=15 
 
Glucuronides reported that do 
not come from human: n=2 
 




























Medicinal drugs are perceived to elicit therapeutic effects to treat or manage a 
disease. However, there is misconceptions in the views of medicinal drugs. This 
is because each individual responds to a drug due to different efficiencies of 
drug detoxification, which can be linked to linked to the genetic makeup of an 
individual. However, current practices of prescribing and administering drugs 
does not consider the genetics of an individual and therefore, should be 
considered before prescribing a drug to a patient (Zineh et al. 2004; Frueh et al. 
2008). Thus, an individual may present severe adverse toxicological reactions 
to a drug that has been prescribed for treatment, since the standard method is a 
“one fits all approach”. Therefore, the application of personalised medicine 
should be considered as a standard practice for prescribing medicinal drugs. 
Personalised medicine is designed to tailor a drug or treatment to a patient 
based on the genetics of a patient (Younossi et al. 2013; Guglielmo et al. 2018). 
Thereby, personalised medicine could prevent the risks of adverse toxicological 
reaction caused by a prescribed drug, potentially achieving a higher success 
rate for disease treatment. Below discusses the implications of how genetic 
variation can alter the detoxification of medicinal drugs.  
 
3.1 Irinotecan  
3.1.1 Irinotecan overview  
Irinotecan (CPT-11) (Figure 3.1) is a chemotherapeutic-based drug for the 
treatment of colorectal cancers (CRCs) (Morise et al. 2014) and small cell lung 
cancers (SCLCs) (Kondo et al. 2018). CPT-11 inhibits topoisomerase I by a 
binding mechanism preventing DNA ligation, reparation and replication (Fayad 
et al. 2009; Tamura et al. 2012; Meisenberg et al. 2016). This promotes the 
induction of the apoptotic pathway, triggering cellular death to cancerous cells 















Figure 3.1: Molecular structure of irinotecan  
 
In CRC’s CPT-11 is administered as the first drug for treatment if the CRC 
metastasises. CPT-11 is usually co-administered with cetuxumab or fluoruracil 
(5-FU) and folinic acid (FOLFIRI) (Figure 3.2), as a drug combination therapy 
(Uemura and Yamada 2006; Ruzzo et al. 2008; Huang et al. 2012; Pham et al. 
2015; Liang et al. 2016). The FOLFIRI drug regime treatment aims to reduce 
the size of CRCs. Liang et al. (2016) reported that before treatment the 
metastases size (mm) of 218.71 ± 38.57 and after treatment the metastases 
size has been reduced with a size of 63.09 ± 12.69. Therefore, the FOLFIRI 
treatment is effective on CRCs. Despite this evidence, chemotherapy-drug 










Figure 3.2: Molecular structure of fluoruracil and folinic acid   
 
CPT-11, unlike its use for CRCs, is the second choice of treatment for SCLCs. 
SCLC’s account for approximately 15% of all cancers of the lung. Kondo et al. 
(2018) concluded that CPT-11 achieved a high disease control rate (DCR) and 
increased survival time in patients. Despite the small sample size (n=30) of this 




with CPT-11, reported a low dosage (60 mg) was effective with minor 
toxicological effects (Morise et al. 2014). This suggests that high drug dosage 
may not reflect a higher efficacy.  
 
3.1.2 Irinotecan processing by cytochrome p450 
In phase I CPT-11 is a substrate for CYP3A4. CYP3A4 prepares CPT-11 for 
phase II by a oxidative for phase II glucuronidation (Santos et al. 2000; 
Mathijssen et al. 2004). The oxidative reaction synthesises two inactive 
metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-
piperidino]carbonyloxycamptothecin (APC) and 7-ethyl-10-(4-amino-1-



















































Figure 3.3: CPT-11 detoxification pathway. When CYP3A4 reacts with CPT-11, two 
inactive metabolites are produced, APC and NPC. APC and NPC could then go 
through a  esterification reaction catalysed by carboxylesterase (CE). Alternatively, 
CPT-11 can be synthesised to SN-38by an esterification reaction CE. SN-38 can then 
be glucuronidated by UGT1A1.  
 
 
The oxidative reaction catalysed by CYP3A4 protein produces the inactive 
metabolite APC. APC can be synthesised to SN-38, by an esterification reaction 
that is catalysed by carboxylesterase (CE) (Guichard et al. 1998; Wu et al. 
2002; Sanghani et al. 2004; de Jong et al. 2006; Han et al. 2009; van der Bol et 
al. 2011; Marangon et al. 2015; Satoh et al. 2018), (Figure 3.3). NPC is also 
synthesised to SN-38 by CE (Figure 3.3). Alternatively, CPT-11 can be 
synthesised directly to SN-38 by an esterification reaction by CE, or a hydrolysis 




















(glucuronic acid, UDP-GA) for phase II detoxification, synthesising SN-38 
glucuronide. 
 
SN-38, like the parent molecule CPT-11, inhibits topoisomerase I as discussed 
in Section 3.1.1. In CRCs the CYP3A4*20 polymorphism is expressed, with a 
reduced function (Apellániz-Ruiz et al. 2015; Gómez-Bravo et al. 2018). The 
reduced function is a result of protein truncation (Westlind-Johansson et al. 
2006; Zhou et al. 2011; Apellániz-Ruiz et al. 2015). Rierra et al. (2018) 
demonstrated that CYP3A4*20 protein function could be increased. Thereby, 
this may indicate that gene expression can vary in different human ethnicities. 
Alternatively, there could be a lack of research associating the expression 
patterns of CYP3A4*20.   
 
The CYP3A4*20 (rs67666821) polymorphism is more frequently observed in the 
Spanish population (Table 3.1). It has been hypothesised that the founder effect 
is the main cause for the polymorphism (Apellániz-Ruiz et al. 2015). The 
founder effect explains that the loss of genetic variation, is a result of the 
formation of a new population from a small number of individuals who came 
from a larger population (Mayr 1942; Robertson 1952; Mayr 1959; Mckusick et 
al. 1964). Thereby, the founder effect can introduce characteristics that may 

















Table 3.1: Allele distribution frequency of the CYP3A4*20 allele in different 




















NS* NS* NS* 0 (Zhou et al. 
2017) 
Germany NS* 0 <0.1 (Westlind-
Johansson 
et al. 2006) 
Sweden 0 NS* <0.1 (Karczewski 
et al. 2019) 
Italy NS* 0 NS* (Apellániz-
Ruiz et al. 
2014) 
Spain NS* 24 1.6 (Apellániz-
Ruiz et al. 
2014) 
 Argentina NS* 0 0 Apellániz-








NS* NS* NS* <0.1 (Zhou et al. 
2017) 
Libya NS* 0 0 (Apellániz-
Ruiz et al. 
2014) 
Algeria NS* 0 0 (Apellániz-




NS* 1 0 (Apellániz-
Ruiz et al. 
2014) 
NS* 0 NS* <0.1 (Karczewski  
et al. 2019) 
 
Asian 




NS* NS* 0 (Zhou et al. 
2017) 
*NS: Not specified 
 
3.1.3 Phase II detoxification of irinotecan 
CPT-11 requires phase II conjugation for detoxification. CPT-11 is conjugated to 
UDP-glucuronate (UDP-GA, glucuronic acid) by UGT1A1 and UGT1A6. 
UGT1A1 is the predominant UGT1A for CPT-11 glucuronidation (Ando et al. 
1998; Iyer et al. 2002; Marcuello et al. 2004; Alkharfy et al. 2013; Jannin et al. 
2017; Shirasu et al. 2019). The glucuronidation of CPT-11 by UGT1A1 is 
altered by a polymorphism associated which influences toxicological reactions. 
 
UGT1A1*28 alters the fate of CPT-11 molecules by contributing to the 




causes neutropenia and severe diarrhoea, a common adverse effect in 
individuals who have the UGT1A1*28 polymorphism. UGT1A1*28 has a two 
base pair (bp) insertion (thymine (T) and adenine (A) ((TA)7) within the TATA 
box in the promotor region of the gene. The wildtype (WT) UGT1A1 promotor 
region has a sequence of (TA)6 (Ando et al. 1998; Peters et al. 2003; Liu et al. 
2008; Zhao et al. 2013; de Souza 2017). Therefore, before administering 
medicinal drugs, patients should be screened for polymorphisms of UGT1A. 
Human allelic distributions of UGT1A1*28 have been provided in Table 3.2. 
 
 
Table 3.2: Human allele distribution of UGT1A1*28.  
 
*NS: Not specified 
 
UGT1A6 is the second UGT1A that can glucuronidate CPT-11. But, UGT1A6 is 
not as extensively studied as UGT1A1 (Hanioka et al. 2001; Carlini et al. 2005; 
Mross et al. 2007; Bellemare et al. 2010; Stingl et al. 2014; Wang et al. 2017). 
However, no polymorphism of UGT1A6 has yet been associated with altered 


























UK 5 9 3 (5) 26 (44) NS* (Premawardhena 
et al. 2003) 
Iceland 69 7 (10.1) 33 (47.8) NS* (Premawardhena 
et al. 2003) 
Germany  343 39 (17.9) 80 (36.7) NS* (Borucki et al. 
2009) 




47 4 (4.85) 19 (40.4) NS* (Premawardhena 
et al. 2003) 
 
Asia 
Chinese 50 1 (2) 11 (22) NS* (Premawardhena 
et al. 2003) 
Japanese  8 1 (13) 2 (25) NS* (Liu et al. 2007) 
Filipino  37 0 9 (24) NS* (Liu et al. 2007) 




3.1.4 Irinotecan transportation for elimination 
CPT-11 is a substrate for multiple transporters: ABCC4 (multidrug resistance 
protein 4 (MRP4, MOATB)) (Norris et al. 2005), ABCG2 (breast cancer 
resistance protein, BCRP) (Zhang et al. 2008) and ABCB1 (MDR1) (Iyer et al. 
2002). ABCC4 is predominantly expressed in the prostate (Ho et al. 2008) and 
colon (Chen et al. 2017). ABCG2 is also expressed in the colon (Candeil et al. 
2004), duodenum (Gutmann et al. 2005), small intestines (Enokizono et al. 
2007), and seminal vesicles (Thompson et al. 2008). This demonstrates that the 
expression of transporters is not limited to one location. 
MDR1 is the predominant transporter for CPT-11 and SN-38 but, there are 
other ABC transporters for both molecules (Lalloo et al. 2004) In colorectal 
cancers, ABCB1 is over-expressed (Bessho et al. 2006; Riganti et al. 2009; 
Stein et al. 2012; Takács et al. 2015; Liu et al. 2017). Over-expression of 
ABCB1 impedes cancer treatment, causing chemo-resistance towards drug 
based therapies. This will therefore, promote CRC to develop and metastasise.  
Therefore, ABC transporter inhibitors could be used to reduce ABCB1 over-
expression. Furthermore, in colorectal cancers, rs1045642 has been linked to 
reduced expression (Hoffmeyer et al. 2000; Brant et al. 2003; Shahwan et al. 
2007; Drain et al. 2009; Campa et al. 2012; Marna et al. 2015; Jin and Song 
2017). Decreased expression may influence an accumulation in toxic molecules 
which could contribute to further disease progression. 
Similarly to MDR1, MRP4 is also over-expressed in CRC (Holla et al. 2008; 
Cheung et al. 2015). The overexpression of ABCC4 also renders drug-based 
chemotherapy ineffective (Gradilone et al. 2008; Lai et al. 2012; Zhang et al. 
2014). The over-expression of ABCC4 has been observed in cancers such as: 
neuroblastomas (Norris et al. 2005), colorectal cancer (Holla et al. 2008), 
prostate cancer (Ho et al. 2008) lung cancer (Maeng et al. 2014) and 
osteosarcomas (He et al. 2015). Alternatives to drug-based cancer treatments 
could be used to minimise the risk of chemo-resistance in the presence of over-
expressed ABC transporters. 
A variant of the ABCG2 gene is associated with promoting further adverse 




myelosuppression (Cha et al. 2009; Wang et al. 2011; Moriya et al. 2014; 
Bircsak et al. 2018). Myelosuppression decreases bone marrow activity and as 
a result, reducing the production of red blood cell (RBC) and platelets 
(Warkentin et al. 2014; Taylor et al. 2017). Before prescribing CPT-11, it is 
recommended that patients should be screened for rs3109823 and 
UGT1A1*28. 
 
3.1.5 Irinotecan and disease 
With an altered detoxification pattern of CPT-11, the application of CPT-11 for 
CRC treatment is ineffective (Bessho et al. 2006; Riganti et al. 2009;Lai et al. 
2012; Zhang et al. 2014). This is due to that in the presence of UGT1A1*28 
glucuronidation of CPT-11 and SN-38 is significantly reduced. Consequently, 
CPT-11 and SN-38 accumulate in the liver inducing adverse effects (Section 
2.1.3). Furthermore, with the presence of rs3109823, a variant affecting 
ABCG2, influences further adverse effects (Section 2.1.4). Therefore, 
alternatives of CPT-11 for treatment programmes could be considered. 
Furthermore, genotyping a patient for the variants is recommended (Campa et 
al. 2012; de Souza et al. 2017; Sharma et al. 2019), to avoid adverse 
toxicological reactions towards a drug. Thus, the application of personalised 
medicine for the treatment of CRC should be considered. 
 
3.2 Acetaminophen  
3.2.1 Acetaminophen overview 
Acetaminophen (APAP, paracetamol), is an analgesic drug used to treat acute 
to moderate pain (Chou et al. 2007; Toms et al. 2008). The mechanism of 
action of APAP is to inhibit prostaglandin (PGs) synthesis (Rahme et al. 2002; 
Högestätt et al. 2005). PGs are synthesised by cyclooxygenase-1 (COX-1) and 
cyclooxygenase-2 (COX-2) (Figure 3.4), to promote inflammation at the site of 
injury or infection. APAP is a weak inhibitor of COX-1 and COX-2 but, APAP 
does not inhibit COX-1 and COX-2 in peripheral tissues (Rahme et al. 2002; 




not classified as a nonsteroidal anti-inflammatory drug (NSAID) because APAP 
does not relieve inflammation. 
 
Figure 3.4: Diagram of acetaminophen inhibiting prostaglandin synthesis. The 
mechanism for inhibition of COX-2 remains unclear.  
 
3.2.2 Acetaminophen detoxification by cytochrome p450  
When APAP is present in the liver, CYP3A4 gene expression is stimulated, 
coding for CYP3A4 protein. CYP3A4 bioactivates APAP by an oxidative 
reaction (Figure 3.5). However, CYP3A4 activity can be suppressed by APAP in 
a dose-dependent relationship (Feierman et al. 2002; Zhang et al. 2004; Kim et 
al. 2009; Ben-Shacher et al. 2012; Raza and John 2015; Limonciel et al. 2018). 










Figure 3.5: Phase I detoxification of acetaminophen by CYP3A4. NAPQI is the 
active metabolite produced from the oxidation reaction which can induce toxicological 
effects. 3-OH-Acetaminophen is an inactive metabolite produced from the reaction. 
 
Other CYP450s can prepare APAP for phase II, CYP2E1 and CYP1A2. 
CYP2E1 and CYP1A2 were the first two reported CYP450s to react with APAP. 




acetyl-p-benzoquinone imine (NAPQI or NAPBQI) (Zaher et al. 1998; Sumioka 
et al. 2001; Guo et al. 2004; Dai et al. 2006). The presence of NAPQI in the liver 
can promote adverse toxicological effects including liver damage (Fong et al. 


































Table 3.3: Human allele distribution of CYP2E1*5B  
*N: population size; P-value presents significance difference. P-values are the values 
reported in the studies. 
 
Interestingly, there is a potential epigenetic mechanism that has been 
postulated to protect the liver from APAP induced liver damage, using miR-122 
(Chowdhary et al. 2017), discussed below. Typically, miR-122 is associated 
with decreasing cholesterol and fatty acids (Esau et al. 2006; Ghosh et al. 2010; 
Wang et al. 2013; Raitoharju et al. 2016; Sendi et al. 2018). The general 
Population  N*  CYP2E1 P- 
value 
References 
    Genotype frequency (%)   
    *1A/*1A *1A/*B *5B/*5B   
    (GG) (GC) (CC)   
Asian         
Iranian  200  97.0 3.0 0.0  (Shahriary et al. 
2012) 
Taiwanese  231  58.0 35.1 6.9 <0.001 (Wang et al. 
1999) 




 166  80.6 NS* 40 <0.001 (Wang et al. 
2009) 
Japanese  NS*  NS* NS* 60 <0.001 (Krishnakumar 
et al. 2011) 
         
European         
French  172  91.6 4.7 0.0 0.29 (Bouchardy et 
al. 2000) 
British  155  96.8 3.2 0.0 0.88 (Yang et al. 
2001) 
German  297  94.9 4.4 0.7 0.11 (Neuhaus et al. 
2004) 
Poland  316  94.4 5.6 0.0 0.08 (Gajecka et al. 
2008) 
Italian  245  93.4 6.2 0.4 0.03 (Boccia et al. 
2008) 
         
American         
Brazilian  212  88.2 11.8 0.0 <0.001 (Marques et al. 
2006) 
American  399  96.2 3.8 0.0 0.6 (Liu et al. 2001) 




 239  72.0 23.8 4.2 <0.001 (Gordillo-




 99  21.2 54.5 24.2 <0.001 (Gordillo-
Bastidas et al. 
2010) 





function of miRs has been discussed in Section 1.3.4 and presented in Figure 
3.7.  
 
Figure 3.7: miRNA synthesis and mRNA degradation pathway. miRNA synthesis 
occurs by a small series of cascade events. miRNA is first synthesised through 
transcription by RNA polymerase II, producing a primary (pri)-miRNA transcript with 
hairpin structure (Lee et al. 2004; Gatfield et al. 2009; Nagpal et al. 2013; Nakamachi, 
et al. 2016). Subsequently, DROSHA proteins (type III ribonuclease), cleave the pri-
miRNA hairpin structure to yield pre-miRNA (Ma et al. 2013; Johanson et al. 2015; Kim 
et al. 2017). From the nucleus of the cell, exportin (EXPO5) transports the pre-miRNA 
to a DICER complex in the cytoplasm, which cleaves pre-miRNA to release the mature 
miRNA for mRNA degradation. 
 
In APAP induced liver toxicity, miR-122 expression is altered but, further 
elucidation is required into the function of miR-122 and protecting the liver from 
APAP induced damage (Chowdhary et al. 2017). Chowdhary et al. (2017) 
reported that if miR-122 expression is decreased, it is correlated with decreased 
expression of two transcription factors, HNF4α and HNF6. These transcription 
factors may regulate APAP detoxification by increasing CYP2E1 and CYP1A2 
expression. Additionally, miR-122 was found to regulate CYP1A2 expression 
through a pathway involving transcriptional repressor CTCF, aryl hydrocarbon 
receptor (AHR) (increased expression), and the mediator of RNA polymerase II 
transcription subunit 1 (MED1, transcription regulator) (increased expression) 
(Chowdhary et al. 2017). The specific molecular mechanism(s) were not 





3.2.3 Acetaminophen phase II detoxification 
APAP and NAPQI can be detoxified by glucuronidation or GSH conjugation 
(Chen et al. 2003; Srikanth et al. 2005). If APAP and NAPQI are detoxified by 
glutathione (GSH) conjugation, one of the three GSTs could conjugate GSH 
molecules to APAP or NAPQI: GSTT1, GSTP1 and GSTM1 (Huber et al. 2009; 
Roušar et al. 2012; Raza et al. 2015; Kim et al, 2018). The conjugation reaction 
synthesises APAP-GSH and NAPQI-GSH metabolites (Figure 3.8). However, 
discussed in Section 3.2.4, excess APAP and NAPQI can induce liver necrosis 
and liver failure, due to depleted concentrations of GSH in the liver.  
 
Figure 3.8: Phase II detoxification of acetaminophen and NAPQI. The metabolites 
produced at the end of the conjugation has glutathione conjugated to each of the 
molecules.  
 
Glutathione S-Transferase Theta 1 (GSTT1) is one of the three GSTs capable 
of detoxifying APAP molecules and NAPQI metabolites. A gene deletion of 
GSTT1 influences susceptibility towards APAP inducted liver toxicity (Lucena et 
al. 2008; Buchard et al. 2012). The consequence of the gene variant contributes 
to APAP induced liver hepatotoxicity since GSH is not conjugated to APAP for 
detoxification. However, there are two other GSH conjugation enzymes for 
NAPQI and APAP GSH conjugation. Thus far, other research is needed to 
explore whether there are other GSTT1 variants which may influence APAP 
induced hepatotoxicity.  
 
A variant of GSTP1, GSTP1 Ile/Ile, is thought to influence the risk of asthma 




(2018), the authors commented on a 1.8 times increased risk of asthma 
occurrence when infants are exposed to APAP, with the GSTP1 Ile/Ile variant. 
In other research it has been demonstrated that individuals with the Ile/Ile 
genotype are at a higher risk of asthma from pollutants (Schultz et al. 2010; 
Hwang et al. 2013; Al-Arifa and Jahan 2016). This suggests that the function of 
GSTP1 with the Ile/Ile genotype is reduced. 
 
Glutathione S-transferase Mu 1(GSTM1) is a third GST, conjugating GSH to 
APAP and NAPQI. Alike to GSTT1, GSTM1 can also be deleted causing a 
potential predisposition to APAP induced liver failure (Lucena et al. 2008; 
Buchard et al. 2012). Allele frequency of GSTM1 deletion was not identifiable. 
Clearly, further research is needed to find an association between potential 
GSTM1 variants and APAP induced hepatotoxicity.  
 
APAP is also conjugated to UDP-GA for detoxification by UGT1A protein. Both 
UGT1A1 and UGT1A6 can glucuronidate APAP. This has been reported in 
some studies (Mutlib et al 2006; Osabe et al. 2008; Liu et al. 2011; Giamarellos-
Bourboulis et al. 2014; Mehboob et al. 2017). However, if an individual with 
Gilbert’s syndrome self-administers APAP, glucuronidation of APAP is reduced 
(Esteban et al. 1999; Ito et al. 2002; Rauchschwalbe et al. 2004). Individuals 
with Gilbert’s syndrome are unlikely to detoxify APAP effectively. As a result, 
those with Gilbert’s syndrome are likely to develop liver damage.  
 
3.2.4 Phase III transportation of acetaminophen 
ABCC4 codes for multidrug resistance protein 4 (MRP4) whilst, ABCC12 
encodes for cystic fibrosis transmembrane regulator (CFTR) and multidrug 
resistance protein 9 (MRP9). A limited number of studies have reported induced 
expression of ABCC4 and ABCC12 induced by APAP (Zamek-Gliszczynski et 
al. 2006; Aleksunes et al. 2008; Khan et al. 2011; Schäfer et al. 2013; Lima et 
al. 2015). Which therefore draws the conclusion that MRP4 and MRP9 
transports APAP for excretion from the cell. But, increased concentrations of 
APAP leading to APAP induced liver damage and failure, leads to the up-




2006; Campion et al. 2008) and a human liver sample study (Barnes et al. 
2007). The increased ABCC4 expression may also account for an increase in 
other potential toxic molecules that could be associated with APAP induced liver 
damage and failure.  
 
Therefore, to date the only known pathological effect of which APAP induces is 
liver failure and damage (Fong et al. 2010; Stutchfield et al. 2015; Rubin et al. 
2018). This is because APAP and the toxic metabolite, NAPQI, depletes GSH 
molecules in the liver. Consequently, NAPQI interacts with molecules in the liver 
(Mitchell et al 1973; Miner and Kissinger 1979; Dybing et al. 1983; Moore et al. 
1985; Farber et al. 1988; Trenti et al. 1992), inducing liver necrosis and failure. 
There are also other contributing factors that could influence APAP induced 
hepatotoxicity such as gene variants that code for glutathione conjugating which 
yet, needs to be explored.  
 
3.3 Hydrocortisone  
3.3.1 Hydrocortisone overview 
Cortisol is a glucocorticoid that can be used for medicinal application , referred 
to as hydrocortisone, that is commonly used as creams (Figure 3.9). The 
medicinal applications of hydrocortisone is to treat a number of skin conditions 
including: eczema (Korting et al. 1995) and dermatitis (Jorrizo et al. 1995). The 
mechanisms of action of hydrocortisone involves the binding of hydrocortisone 
molecules binding to glucocorticoid receptors (Ayrout et al. 2017), which leads 
to the formation of a receptor-ligand complex. This complex subsequently 
translocates to the cell nucleus and binds to a glucocorticoid response element 
(GRE) of the targeted gene(s) to regulate expression (Rainville et al. 2017). 
Additionally, hydrocortisone possess anti-inflammatory properties via the 
suppression of COX-1 and COX-2 preventing the synthesis of PGs (Kirkby et al. 
2012; Dong et al. 2018). Thus, this demonstrates that hydrocortisone has a 
number of influences on molecular processes. Alike to other medicinal drugs 













Figure 3.9: Molecular structure of Hydrocortisone.  
 
Other applications of hydrocortisone include hormone therapy treatment for 
diseases. For instance, in Addison’s disease cortisol production is reduced due 
to dysfunction of the adrenal glands (Kyriazopoulou et al.1984; Candrina and 
Giutina 1987). Thus, hydrocortisone is used to restore cortisol concentrations in 
a patient with Addison’s disease (Baxter et al. 2013; Murray et al. 2016). 
Therefore, not only hydrocortisone can be used for dermatological conditions 
and allergies but, it can also be used for hormone replacement therapy for a 
disease.  
 
3.3.2 Hydrocortisone and phase I and phase III detoxification 
Hydrocortisone is a substrate of CYP3A4 in phase I of the detoxification 
pathway. The expression of CYP3A4 is influenced by the concentration of 
hydrocortisone. The encoded protein by CYP3A4 hydroxylates hydrocortisone 
to synthesise 6β-hydroxycortisol (Kuzikov et al. 2019), Figure 3.10. Once 6β-
hydroxycortisol has been synthesised, the metabolite is subsequently effluxed 
out from the cell by MDR1 (encoded by ABCB1) (Kyle et al. 2018) and then 
eliminated from the body. Thus, to date it is not elucidated that 6β-










Figure 3.10: Phase I detoxification of hydrocortisone. CYP3A4 detoxifies 
hydrocortisone by a hydroxylation reaction.  
 
3.3.3 The undesired effects of hydrocortisone  
In despite of the medicinal applications of hydrocortisone there are 
considerations that should be taken into account. However the use of 
hydrocortisones could promote adverse effects including indirect effects of 
disease causation such as Type 2 Diabetes Mellitus (T2DM) (Kamba et al. 
2016; Sue and Milanes 2019). As discussed in Section 2.3.1, hydrocortisone 
increase cortisol concentrations. Increased cortisol concentrations can lead to 
increased blood glucose concentrations (Vila et al. 2010; Kamba et al. 2016; 
Lakhani et al. 2017). Therefore, hydrocortisone acts as an indirect cause for the 
development of T2DM. Furthermore, individuals with T2DM should avoid the 
use of hydrocortisone since, hydrocortisone could increase the severity of 
T2DM by promoting a further increase in blood glucose concentrations.      
 
Furthermore, it should be recognised that T2DM can also be influenced by a 
individual’s lifestyle choice. It is evident that individuals who consume a high fat 
and glucose containing diet, accompanied with the lack of exercise is a 
contributing factor (Lindström et al. 2006; Nisar et al. 2009; Ganiyu et al. 2013; 
Cassidy et al. 2016; Barreira et al. 2018). Furthermore, T2DM can  also 
influenced by genetics. In a study conducted by Eny et al. (2008), reported that 
a variant in GLUT2, Thr110Ile, has influential roles contributing to an increased 
consumption of a higher glucose intake. Furthermore, in a genome-wide DNA 
methylation study, multiple genes have been reported to have methylation 
including CYP7A1 (Guo et al. 2019). The CYP7A1 gene encodes for the 
CYP7A1 protein which is important for the metabolism of cholesterol (Pullinger 




could prevent the metabolism of cholesterol and therefore, cholesterol could 
accumulate in the human body contributing to obesity and in turn, T2DM. In 
despite of the presence of a gene variant and epigenetic regulatory 
mechanism(s), the variant and epigenetic mechanism(s) may not be the sole 
cause of the disease. Therefore, the prescribing of hydrocortisone to a patient 
should be done with caution. This is because if patients who are prescribed 
hydrocortisone with undiagnosed T2DM as a result of lifestyle or genetic 
influences, the severity of T2DM could be increased. Furthermore, T2DM is 
currently determined  by determining blood glucose concentrations but 
associating glucuronides to T2DM could also be used. Thus far, only two 
research papers have reported glucuronides associated with T2DM (Appendix 2 
and see Table 8.3).   
 
3.4 Clotrimazole 
3.4.1 Clotrimazole overview and cytochrome p450 
Clotrimazole (Figure 3.11) is another dermatological cream based treatment for 
fungal based infections including: thrush (Reddy et al. 2017), ringworm (Trivedi 
et al. 2017) and athlete’s foot (Abed and Hussein 2017). The mechanisms of 
action of clotrimazole suppresses the synthesis of ergosterol within fungal 
membranes, preventing fungal cell wall synthesis (Taylor et al. 1983; Haller 
1985). The suppression of ergosterol synthesis is influenced by a dose 















To date, studies have reported that clotrimazole is able to suppress: CYP2E1 
(Zanger et al. 2000), CYP1A2 (Zhang et al. 2002), CYP2D6 (Zhang et al. 2002) 
and CYP3A4 (Monostory et al. 2004). Conversely, clotrimazole has been 
reported to induce CYP2B6 expression (Faucette et al. 2004). Therefore, in 
vivo, the suppression of the named CYP450s may allow drug-drug interactions 
to occur which could potentially be toxic to an individual who use clotrimazole 
and other medicinal drugs. However, the molecular interaction for phase I 
detoxification of clotrimazole by CYP2B6 is unclear.  
 
3.4.2 Clotrimazole and phase II and phase III 
Alongside with interfering with phase I detoxification, clotrimazole can also 
interfere with phase II conjugation of other molecules. In one study, Das et al. 
(1986), reported clotrimazole can interfere with glucuronidation and sulphation 
of polycyclic aromatic hydrocarbons (PAHs), using primary neonatal BALBlc 
mouse keratinocyte cell cultures. However, thus far, there is not further 
research exploring the effects of clotrimazole and phase II conjugation.  
 
In humans an association of clotrimazole and ABC transporters are yet to be 
revealed. However, in a study using Saccharomyces cerevisiae revealed 
clotrimazole is a substrate of Pdr5p (Knorre et al. 2016). Pdr5p is a nucleotide 
triphosphate (NTP)-dependent transporter which relies on NTP for the efflux of 
molecules from the cell. Additionally, the Pdr5p transporter is studied for 
antifungal resistance (Reis de Sá et al. 2014). Clearly, further research is 
required to elucidate whether clotrimazole is transported in humans or whether, 
clotrimazole interferes with the transport of other molecules.  
 
3.4.3 Clotrimazole and disease  
Clotrimazole and other azole based anti-fungal treatment not only has 
antifungal properties, but they can induce toxicological reactions (Khoza et al. 
2017; Bühler et al. 2019). Clotrimazole is thought to induce hepatotoxicity and 
clotrimazole induced hepatotoxicity. This  can be tested by determining liver and 
blood plasma concentrations of aspartate aminotransferase (AST), and alanine 




human case report study (Bühler et al. 2019). However, further research is 
recommend. However, monitoring a patient on a drug should be considered to 
monitor and identify potential changes in molecular biomarkers, which could 
indicate toxicity and other adverse effects.  
 
3.4 Conclusion 
In despite of the perception of medicinal drugs and their medicinal properties, 
medicinal drugs can influence other complications such as Type 2 Diabetes 
Mellitus by hydrocortisone. Therefore, it is recommended that patients with type 
2 diabetes mellitus, should not use hydrocortisone and caution must be taken if 
a patient has undiagnosed type 2 diabetes mellitus. Additionally, medicinal 
drugs also change the fate of a molecule during detoxification. In despite of 
there has not been a disease associated with clotrimazole but, the anti-fungal 
treatment has capabilities of inducing hepatotoxicity. Similarly, acetaminophen 
depletes glutathione molecules in the liver, which leads to hepatotoxicity and 
this may lead to acetaminophen related deaths depending upon the severity of 
the damage in the liver caused by acetaminophen. The toxicity of irinotecan is 
influenced by a number of variants namely, UGT1A1*28 (associated with 
neutropenia and severe diarrhoea) and ABCG2 rs3109823 influences 




































Unlike medicinal drugs, illicit drugs are used for recreational purposes, by which 
a illicit drug acts upon the central nervous system (CNS), altering the state of 
mind of the illicit drug user. Illicit drugs such as cocaine promotes brain 
stimulation by enhancing dopamine production by binding to dopamine 
receptors (Navarro et al. 2013; Dobbs et al. 2016; Wang et al. 2019), which can 
therefore lead to enhanced senses such as hallucinations and altered 
behavioural patterns. Furthermore, the use of heroin can lead to mental health 
disorders including: anxiety (Applebaum et al. 2010), depression (Cornford et al. 
2012), bipolar (Maremmani et al. 2012), and schizophrenia (Chiappelli et al. 
2017). This clearly demonstrates there are multiple adverse effects associated 
with illicit drugs. However, gene variants within the detoxification pathway can 
alter the fate of the drug (Bunten et al. 2010; Levran et al. 2013). The purpose 
of this chapter is to discuss the metabolomic fate of different illicit drugs.   
   
4.1 Methadone  
4.1.1 Methadone and phase I detoxification  
Methadone, a narcotic, is an illicit synthetic opiate (Figure 4.1) but methadone 
has also been used for medicinal applications (Lossignol et al. 2013; 
Rasmussen et al. 2015; Mercadante and Bruera 2018). Methadone is used in 
treatment programmes to withdraw individuals from illicit opioid addictions 
(Amato et al. 2003; Ilgen et al. 2006). Additionally, methadone can be used as 
an alternative to morphine for pain treatment (Shelton et al. 2008; Verthein et al. 
2014). Both methadone and morphine bind to the mu (μ)-opioid receptor 
(OPRM1), to elicit therapeutic effects. Methadone is administered as a racemic 
mixture consisting of (R-) and (S-) enantiomers (Bunten et al. 2011; Chen et al. 
2014; Peng et al. 2018). However, the use of methadone can also lead to 


















Figure 4.1: Molecular structure of methadone. The left presents the (R)-enantiomer 
whilst the right presents the (S)-enantiomer of methadone.  
 
The (R)-enantiomer of methadone is responsible for eliciting therapeutic effects 
and conversely, the (S)-enantiomer is toxic (Lamont et al. 2006; Eap et al. 
2007). The toxicity of the (S)-enantiomer (Eap et al. 2007; Lin et al. 2009), is 
due to inhibition of sodium/potassium (Na+/K+) pumps. The inhibition of Na+/K+ 
pumps causes prolonged QT intervals of a heartbeat. Consequently, Torsades 
de pointes (polymorphic ventricular tachycardia) occurs, demonstrated by rapid 
and irregular QRS complexes on an electrocardiogram (ECG) (Lamont et al. 
2006; Viskin et al. 2010; Price et al. 2013; Nicotera et al. 2016). Thereby, 
individuals who have Torsades de pointes may have spontaneous ventricular 
fibrillation. Thus, CYP2B6 has a greater affinity towards the (S)-enantiomer. 
 
CYP2B6 demethylates the (S)-enantiomer producing an inactive metabolite 
(Wang et al. 2010; Gadel et al. 2013; Zahari et al. 2016) (Figure 4.2). The 
inactive metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) is 
subsequently excreted in the urine (Larson and Richards 2009; Leimans et al. 
2012; Holm and Linnet 2015; Musile et al. 2018). The fate of the (R)-enantiomer 
is not clear. Substrate affinities towards methadone of the non-polymorphic 
CYP2B6 are presented in Figure 4.3. The Km represents substrate 









Figure 4.2: Demethylation of methadone by CYP2B6. 
 
 
A)                                                     B)                                              C) 
 
Figure 4.3: Km and Vmax of methadone in the presence of CYP2B6 (Adopted from: 
Gerber et al 2004). A) Km and Vmax of racemic methadone, Km = 14.8 µg/ml, Vmax = 45 
ng/min/10 p mol. B) R-methadone, Km = 73 µg/ml and Vmax = 8.15 ng/min/p mol. C) S-
methadone, Km = 30 µg/ml and Vmax = 3.7 ng/min/p mol. Used with the permission from 
Wiley publishers.  
 
A polymorphism of the CYP2B6 gene, CYP2B6*6, alters the fate of methadone 
due to reduced gene expression. As a result, the (S-) enantiomer of methadone 
is not detoxified effectively, classifying individuals with the polymorphism as 
poor metabolisers, as reported in some post-mortem analysis studies (Bunten 
et al. 2010; Bunten et al. 2011[a]; Bunten et al. 2011[b]; Gadel et al, 2013; 
Kharasch et al. 2016). The kinetic parameters of CYP2B6*6 also show protein 
function is reduced. The (R-) and (S-) enantiomers have an equilibrium 
dissociation (Ks) of 97 ± 7 and 40 ± 7, respectively. The Vmax of (R-) and (S-) 
enantiomers have been reported to be 5.7 ± 0.3 and 3.5 ± 0.3, respectively. 
Conversely, the wild-type (WT) has a Ks of 75 ± 18 for the (R-) enantiomer and 




are 20.8 ± 0.6 and 14.6 ± 1.0, respectively (Gadel et al. 2013). Thus, 
demonstrating kinetic parameters of CYP2B6*6 is reduced. Furthermore, the 
polymorphism is prevalent in the African and Caucasian population (Table 4.1).  
 
 




























NS* Not Specified 
 
In addition to CYP2B6, another CYP450 detoxifies methadone, CYP2D6. A 
transition mutation within CYP2D6, G1934A, introduces a premature stop codon 
causing protein truncation by a splicing defect (Gough et al. 1990; Saxena et al. 
994; McLellan et al. 1997; Duzhak et al. 2000), causing a non-functional variant. 
This defect produces the CYP2D6*4 (rs3892097) variant. Alike to the 
CYP2B6*6 variant, individuals carrying this variant cannot detoxify methadone. 
Therefore, methadone related deaths may occur. CYP2D6*4 affects 
approximately 20% of the European population (Table 4.2). Therefore, both 
CYP2B6*6 and CYP2D6*4 should be screened in post-mortem analysis to rule 





Table 4.2: Human allele distribution of CYP2D6*4   
 
*NS: Not Specified 
 
4.1.2 Methadone and phase II conjugation 
To date, it is not elucidated in research whether methadone and the methadone 
metabolite EDDP can be conjugated to UDP-glucuronate (UDP-glucuronic acid, 
UDP-GA) for glucuronidation (Goldberger et al. 1998). But, methadone is able 
to suppress glucuronidation activities of UGT2B4 and UGT2B7. Raungrut et al. 
(2010) reported that in humans, methadone suppressed glucuronidation activity 
of UGT2B4. In a similar study by Gelston et al (2012), they conducted a study 
which explored the detoxification of codeine and buprenorphine in patients. The 
study reported that methadone suppressed  glucuronidation activity of UGT2B4 
and UGT2B7 for codeine and buprenorphine in humans. Therefore, if there is a 
non-functional variant of either CYP2B6 or CYP2D6, methadone molecules 
could accumulate and suppress glucuronidation activities of UGT2B4 and 
UGT2B7. The consequent suppression of glucuronidation activities may allow 
other toxic molecules including methadone to accumulate and as a result, an 
individual may have toxicological reactions due to the presence or toxic 





4.1.3 Methadone and phase III  
In phase III of the detoxification pathway methadone is transported by the P-gp 
ABC transporter for elimination from the body via urination (George et al. 2000; 
Preston et al. 2003).  ABCB1 is expressed in various locations around the body 
including: brain, liver, kidneys, small intestine and colon. Multiple studies have 
reported that methadone is a substrate for MDR1 (Bouër et al. 1999; Wang et 
al. 2004; Ortega et al. 2007; Tournier et al. 2010; Hung et al. 2013; Mouly et al. 
2015; Gibbs et al. 2018). However, methadone transport can be affected by 
other medicinal drugs such as quinidine, due to the suppression of MDR1 which 
increases the concentration of methadone molecules in the blood (Funao et al. 
2003; Rautio et al. 2006; Pires et al. 2009).  
 
Three polymorphisms have been highly studied associated with ABCB1. Three 
main polymorphisms affect ABCB1 expression: rs1128503 (synonymous 
mutation, C1236T), rs2032582 (Ala893Thr, missense mutation, exon 21) and 
rs1045642 (C3435T, synonymous mutation). These three ABCB1 variants alter 
the fate of methadone. 
 
4.1.3.1 rs1128503 
rs1128503 (T1236C) is a synonymous mutation that is thought to have an 
influence on opioid dependence susceptibility (OMIM %610064). This is 
because individuals who have the rs1128503 polymorphism require an 
increased dose of methadone for heroin withdrawal. Individuals with the TT 
homozygous genotype require up to five times more methadone (150 mg/day) 
compared to individuals who have the CT heterozygous genotype and the non-
variant (Levran et al. 2008; Levran et al. 2013). Therefore, rs1128503 may act 
as a predisposition to methadone related fatalities. Allele distributions have 












Table 4.3: Human allele distribution of rs1128503. 
 
4.1.3.2 rs2032582  
rs2032582 is another variant that alters the activity of ABCB1. Two mutations 
can arise from rs2032582: G2667T (Ser893Ala) and G2667A (Ser893Thr). 
Ala893Thr has been observed to reduce transport activity (Rebecchi et al. 2009; 
van Assema et al. 2012; Fehér et al. 2014; Madadi et al. 2016). But it is not 
apparent how Ala893Ser alters transport activity. Both allele distributions have 

















Table 4.4 (A): Allele frequency distribution of ABCB1 rs2032582. Distribution of 
Ser893Ala (Adopted from: Karczewski et al. 2019).  
               
   



















Table 4.4 (B): Allele frequency distribution of ABCB1 rs2032582. Distribution of 





















rs1045642 is a synonymous nucleotide mutation (C3435T). In a similar manner 
to rs1128503 and rs2032582, rs1045642 has been reported to contribute to 




withdrawal if the polymorphism is homozygous (Levran et al. 2013). Thus, 
implying the function of rs1045642 is increased. The molecular function of 
rs1045642 should be explored to reveal whether transport activity is affected. 
Table 3.5 presents the allele distributions of rs1045642. 
 
Table 4.5: Human allele distribution of ABCB1 rs1045642  
 




















188 28 48 (Hoffmeyer et al. 
2000) 
Portugal 92** 56 (35)*** 73 (46)*** (Santos et al. 
2014) 








Saudi Arabia  96 26 38 (Ameyaw et al. 
2001) 
China 132 26 42 (Ameyaw et al. 
2001) 
Han Chinese 185 40 44.32 (Yan et al. 2017) 
 
Africa 
Ghana  206 0.0 3.4 (Ameyaw et al. 
2001) 
Kenya 80 4 26 (Ameyaw et al. 
2001) 




99** 13 (13.1)*** 39 (39.4)*** (Santos et al. 
2011) 
 
NS*: Not specified  
**: Number of patients in study 
***: Patients who have been identified with the polymorphism. (n) = % of those with the 
polymorphism.  
 
Furthermore in phase III, other drugs are able to alter the fate of methadone 
(Kharasch et al. 2004). Quinidine is a medicinal drug, (Figure 4.4), that is 
synthesised to aid in the treatment for heart arrhythmias (Zakrzewska-Koperska 
et al. 2018) and atrial fibrillation (Mazzanti et al. 2019). Quinidine is a substrate 
of MDR1, by which quinidine suppresses transport activity of MDR1 (Funao et 
al. 2003; Rautio et al. 2006; Pires et al. 2009; Syvänen et al. 2012; Bui et al. 
2015; Morsy et al. 2018). Thus, when quinidine is taken by a methadone user, 
plasma concentrations of methadone increase (Kharasch et al. 2004; Kharasch 




which could contribute to methadone related deaths. Therefore, in post-
mortems that are associated with methadone related deaths, quinidine and 












Figure 4.4: Molecular structure of quinidine.   
 
 
4.2 Cocaine  
4.2.1 Cocaine overview and phase I detoxification 
Cocaine is a recreational drug (Figure 4.5), which stimulates the central nervous 
system (CNS) and inhibits the reuptake of serotonin, noradrenaline and 
dopamine  (Tomasi et al. 2010; Kosten et al. 2013; Smith et al. 2015; Siciliano 
et al. 2018). This is one of the molecular characteristics of cocaine addiction. 
Consequently, prolonged exposure and use of cocaine can lead to psychotic 
reactions (auditory and visual hallucinations and paranoia) (Mitchell and 
Vierkant 1991; Cuomo et al. 1994; Bartlett et al. 1997). In phase I detoxification, 
cocaine is detoxified by CYP3A4 (Pasanen et al. 1995; De Rienzo et al. 2000; 
Ramírez et al. 2004; Vitcheva and Mitcheva 2007; Gallelli et al. 2017), by a 
demethylation reaction. Alternatively, cocaine can be detoxified by a 
















Figure 4.5 Molecular structure of cocaine.  
 
If cocaine is detoxified by esterification, the major metabolite benzoylecgonine 
(inactive metabolite), is produced. Alternatively, if cocaine is demethylated by 
CYP3A4, the minor active metabolite norcocaine is synthesised (Kloss et al. 
1983; Plessinger and Woods 1990; Pellinen et al. 1994; Smirnow and Logan 
1996; Arinç and Bozcaarmutlu 2003; Vitcheva and Mitcheva 2007), (Figure 4.6). 
Norcocaine is an active toxic metabolite which can elicit toxicological reactions 
in the liver leading to liver necrosis and failure (Thompson  et al. 1979; Kloss et 
al. 1982).   
 
Figure 4.6: Chemical reaction processing of cocaine. The esterification reaction is 
the major reaction for cocaine producing benzoylecgonine. Whilst the demethylation 








4.2.2 Cocaine and phase II conjugation  
After phase I preparation, like methadone, cocaine does not require 
glucuronidation. This may be due to the resultant major metabolite 
benzoylecgonine of the esterification reaction by carboxylesterase, being 
inactive and non-toxic. Yao et al. (2013) characterised cocaine molecule 
metabolites and glucuronides in murines that are not named. Thus, 
demonstrating that cocaine could be conjugated to UDP-GA but requires further 
exploration. Furthermore, research to date has not revealed whether norcocaine 
is glucuronidated.  
 
4.2.3 Cocaine and  phase III transport 
Cocaine is also thought to be a substrate of MDR1 however, this is based on 
limited knowledge (Raje et al. 2003; Tournier et al. 2010; Isaza et al. 2013; 
Salvatore et al. 2015). Additionally, MDR1 is thought to have an influence in 
cocaine addiction (Candiotti et al. 2013; Salavatore et al. 2015), but evidently 
further research is required. One variant of MDR1 is thought to influence 
cocaine addiction, rs1045642, due to reduced gene expression (Candiotti et al. 
2013; Sychev et al. 2018). Reduced expression may account for an 
accumulation in cocaine molecules in the brain, inhibiting dopamine receptors. 
As a result, dopamine production is reduced which could contribute to addiction 
(Candiotti et al. 2013; Sychev et al. 2018).  
 
Cocaine is also a substrate of a proton-antiporter flux transporter system in the 
blood brain barrier (BBB) (Andrè et al. 2009; Chapy et al. 2014; Chapy et al. 
2015; Auvity et al. 2017). However, the molecular mechanisms of the transport 
system are not clear. Clearly, a further elucidation on the molecular 
mechanisms of the transport system is recommended.  
 
4.3 Ketamine  
4.3.1 Ketamine and cytochrome p450  
Ketamine (Figure 4.7) is used as an illicit drug (recreational) and a medicinal 




drugs discussed above, ketamine acts upon the CNS (Garcia et al. 2008; 
Kittelberger et al. 2012; Tang et al. 2015; Glasgow et al. 2018). The effects of 
ketamine include hallucinations (Hunt et al. 2006), loss of coordination (Hunt et 
al. 2006) and nausea (Heinz et al. 2006). Long-term exposure of ketamine can 
lead to cognitive impairment (Morgan et al. 2006; Nikiforuk et al. 2010; Liang et 
al. 2013). When ketamine is administered, CYP3A4, CYP2B6 and CYP2C9 are 
induced. CYP3A4 has been shown to be the major CYP450 for phase I 
preparation by demethylation (Figure 4.7). CYP2B6 and CYP2C9 have been 
shown to have less activity towards ketamine (Hijazi and Boulieu 2002; Negrusz 
et al. 2005; Legrand et al. 2008; Mössner et al. 2011; Li et al. 2013; Lin et al. 
2015; Zheng et al. 2017). The demethylation of ketamine by CYP3A4 








Figure 4.7: Phase I detoxification of ketamine.  
 
NK is an active metabolite that inhibits the N-methyl-D-aspartate receptor 
(NMDA receptor) (Ebert et al. 1997; Graven-Nielsen et al. 2000). NMDA 
receptors are important for synaptic plasticity and memory. If NK binds to these 
receptors, receptor function is suppressed (Ebart et al. 1997; Liu et al. 2001; 
Negrusz et al. 2005; Stone et al. 2008; Olofsen et al. 2012; Sałat et al. 2015). 
Consequently, memory impairment may occur, influenced by the amount and 
frequency of ketamine use. 
 
Additionally, NK could be converted to 6-OH-norketamine (6-OH-NK) by 
CYP2B6 by hydroxylation (Figure4.8), and subsequently removed from the 
body. NK hydroxylation is also affected by CYP2B6*6 (Li et al. 2013; Li et al. 













Figure 4.8: The conversion of norketamine to 6-OH-norketamine 
 
4.3.2 The fate of ketamine in Phase II and phase III metabolism 
Ketamine molecules do not go through glucuronidation. It is not currently known 
whether glucuronidation of norketamine occurs. A metabolite of ketamine, 3-
OH-norketamine (3-OH-NK) has been observed to undergo glucuronidation 
(Turfus et al. 2009). Therefore, in vivo studies are recommended to reveal 
whether 3-OH-NK is conjugated to UDP-GA for glucuronidation.  
 
In phase III ketamine has been associated with two ABC transporters, ABCB1 
and ABCG2 (Ganguly et al. 2018). Thus, further elucidation is necessary to 
explore the association of ABCB1 and ABCG2. Ketamine may act as an 
inhibitor or inducer for the two transporters.  
 
4.4 3,4-methylenedioxymethamphetamine 
4.4.1 3,4-methylenedioxymethamphetamine and cytochrome 
P450 
3,4-Methylenedioxymethamphetamine (MDMA) is another illicit drug (Figure 
4.9) with stimulatory effects, leading to increased production of serotonin 
(Klomp et al. 2012), dopamine (Hondebrink et al. 2012) and noradrenaline 
(Hysek et al. 2012). When MDMA is taken, enhanced visual hallucinations 
(Lamers et al. 2003) and increased emotions and empathy to other individuals 




psychosis, hypertension, seizures and hyperthermia. Like cocaine, MDMA is 
demethylated by CYP3A4. Additionally, CYP2D6 has also been shown to 
demethylate MDMA (Meyer et al. 2008; de la Torre et al. 2012; Hysek et al. 
2014; Steur et al. 2016; Rodgers et al. 2018). These reactions produce a 
number of metabolites: 3,4-methylenedioxyamphetamine (MDA) from 
detoxification by CYP3A4 (Figure 4.9), 3,4-dihydroxymethamphetamine (HHMA, 
toxic) and 4-hydroxy-3-methoxymethamphetamine (HMMA, inactive), from 
CYP2D6 (Abraham et al. 2009; Antolino-Lobo et al. 2011; Desrosiers et al. 
2013; Steuer et al. 2016), Figure 4.9. These are the known metabolites 




















Figure 4.9: Phase I detoxification of  3,4-Methylenedioxymethamphetamine. 
 
CYP2D6*4 is also associated in altering the fate of MDMA, in a similar manner 
to methadone. A post-mortem analysis study was conducted, involving MDMA 
related deaths. The study reported that CYP2D6*4 may also influence MDMA 
related deaths (Gilhooly et al. 2002), as a result of reduced expression of the 
CYP2D6*4 variant. Therefore, screening for the polymorphism should occur 






4.4.2 3,4-methylenedioxymethamphetamine phase II and phase 
III metabolism 
MDMA molecules are not conjugated to UDP-GA for glucuronidation. However, 
the MDMA metabolite HMMA goes through glucuronidation. Glucuronidation of 
HMMA increases the solubility and reduces toxicity of the molecule. The 
increase in solubility is one of the general effects of glucuronidation (Silva et al. 
2003; van Dorp et al. 2009; Zhang et al. 2014; Taylor et al. 2017). HMMA 
glucuronidation is thought to occur by UGT2B15 (Shoda et al. 2009; 
Schwaninger et al. 2011 [a]) (Figure 4.10), but further research is 
recommended. Alternatively, HMMA can be sulphated by SULT1A3 and 
SULT1E3 (Schwaninger et al. 2011 [b]). Both SULT1A3 and SULT1E3 









Figure 4.10 Phase II detoxification by conjugation of HMMA.   
 
MDMA is thought to be a substrate for ABCB1 (Ketabi-Kiyanvash et al. 2003; 
Tournier et al. 2010). Thus far, it is clear that there is very limited knowledge on 
MDMA and phase III transportation. Therefore, it is recommended that further 
studies should explore other ABC transporters that may transport MDMA. 
Additionally, exploring how variants of a ABC transporter alter the fate of MDMA 






Illicit drugs are taken for recreational uses altering the behaviour of an individual 
by acting upon the central nervous system and receptors within the brain. But 
the detoxification of the drug molecules are influenced by gene variants, which 
could contribute to the severity of the adverse effects within an illicit drug user. 
Furthermore, the presence of non-functional variants of CYP2B6 and CYP2D6 
can lead to drug related deaths. Thus, in treatment programmes such as heroin 
withdrawal using methadone, a patient should be screened for non-functional 








































Food additives are used in foods to maintain food quality, enhance the taste 
and appearance of food (Wang 2000; Prat-Larquemin et al. 2000; Es-Safi et al. 
2000). However, the use of food additives can promote toxic effects  to an 
individual and thus precautions are required before the consumption of food. 
Below discusses the implications of gene variants on different food additives. 
 
5.1 Aspartame 
5.1.1 Aspartame overview and phase I detoxification 
Aspartame is an artificial non-saccharide sweetener synthesised from 
phenylalanine (Phe, F) and aspartic acid (Asp, D) (Figure 5.1), that is used as 
an alternative to sugar (Blackburn et al. 1997; Wang and Schroeder 2000; 
Ilbäck et al. 2003). The acceptable daily intake (ADI) of aspartame is 
approximately 40 mg/kg of body-weight (bw)/day. However, aspartame is highly 
toxic to individuals with phenylketonuria (PKU) (OMIM #261600). PKU is a 
result of a mutation in phenylalanine hydroxylase (Gámez et al. 2000; Muntau et 
al. 2002; Hennermann et al. 2005; Burton et al. 2007; Hoeksma et al. 2009; 
Sanayama et al. 2011; Rossi et al. 2014; Bell et al. 2017), causing an excess 
toxic accumulation of phenylalanine. The consumption of aspartame by 
individuals with PKU can result in seizures and cognitive impairment. However, 








Figure 5.1: Molecular structure of aspartame.  
 
The association of with CYP450s to PKU remains unclear. In despite of this, 
CYP2E1 and CYP3A2 have been associated with increased expression in 
murine models, in the presence of phenylalanine (Labra-Ruiz et al. 2007; Nosti-




CYP2E1 expression has been postulated to be reduced (Mozrzymas et al. 
2017). Thus, further elucidation of the association of PKU and CYP2E1 
expression in humans are recommended. 
 
5.1.2 Aspartame and phase II and phase III detoxification 
Aspartame does not require glucuronidation. Since aspartame is catabolised to 
phenylalanine by phenylalanine hydroxylase, it is not necessary for aspartame 
to go through the detoxification pathway. The phenylalanine produced is used 
as a molecule to synthesise the neurotransmitters dopamine (Mosnik et al. 
1997) and serotonin (Downing et al. 1997). Therefore aspartame does not 
require phase II detoxification. 
 
Upon aspartame metabolism to phenylalanine, L-type amino acid transporters 
(LATs) transport phenylalanine into the brain (Uchino et al. 2002; Møller et al. 
2005; Omidi et al. 2008). LATs are solute carrier (SLC) transporters, requiring a 
sodium (Na+) concentration gradient to transport amino acids (Hidalgo and 
Borchardt 1990; Munck and Munck 1994; Boado et al. 1999). Additionally, LATs 
transport other amino acids including: leucine (Uchino et al. 2002), isoleucine 
(Babu et al. 2003), and threonine (Fernández et al. 2003). Phenylalanine can be 
used as a precursor molecule for neurotransmitter synthesis, such as 
dopamine.  
 
However, in PKU an accumulation of phenylalanine is toxic, which can lead to 
seizures (Harding et al. 2004; Martynyuk et al. 2007). Furthermore, the 
presence of increased phenylalanine can reduce transport of other amino acids 
such as tryptophan (Pietz et al. 1999; Matalon et al. 2006; Mazzola et al. 2012; 
Sanayama et al. 2014). Tryptophan is also a precursor molecule for dopamine 
and serotonin synthesis. In PKU, dopamine and serotonin synthesis is reduced 
in the presence of increased concentrations of phenylalanine (Figure 5.2), 

















Figure 5.2: Phenylalanine transport consequence in phenylketonuria. In 
phenylketonuria, increased concentrations of phenylalanine (Phe) are transported into 
the brain by LAT1. Consequently, dopamine (DA) and serotonin (5-HT) synthesis is 
reduced. As a result, this can contribute to the onset of seizures.  
 
Phenylalanine is a substrate of the broad neutral (0) amino acid transporter 1 
(B0AT1), coded by SLC6A19 (Bröer et al. 2011; Belanger et al. 208). Like to 
other solute carrier transporters they can be expressed in the kidneys and the 
intestines, using a Na+ concentration gradient (Kleta et al. 2004; Pinho et al. 
2007; Fairweather et al. 2009; Bröer et al. 2011; Jiang et al. 2015; Javed et al. 
2018). Phenylalanine transported from the kidneys is eliminated from the body 
by urination.  
 
5.2 Anthocyanins  
5.2.1 The properties of anthocyanins and phase I detoxification 
Anthocyanins (ACs) (Figure 5.3) are pigments producing red to dark red-purple 
colourings in plants (Khoo et al. 2017). The aglycone of ACs, anthocyanidins, 
can be used as food colouring extracts assigned with an E number. E163 (food 
colouring additive) denotes the use of anthrocyanidin (Tennant and Klingberg 
2016). The recommended ADI for ACs as a food additive is approximately 2.5 

















Figure 5.3: Molecular structure of an anthocyanin. Presents the molecular structure 
of cyanidin, a type of anthocyanin. 
 
In vitro studies reported that ACs to have anti-cancerous properties. Zhao et al. 
(2014) reported AC-containing extracts from chokeberries, grapes and bilberries 
inhibited HCT-116 (human colon carcinoma) cancer cell line growth.  A later in 
vitro study Bowen-Forbes et al. (2010), used chokeberries along with other 
fruits including R. acuminatus, R. racemosus, R. jamaicensis and R. idaeus, 
and several cancer cell lines; MCF-7 (breast), SF-268 (CNS), NCI-H460 (lung), 
HCT-116 (colon) and AGS (gastric) to determine AC effects on cancer. The 
study reported ACs from R. acuminatus shown the highest inhibition of cancer 
cell growth. Thi and Hwang (2018) tested AC properties on a SK-Hep1 (human 
hepatic adenocarcinoma) cell line, demonstrating the inhibition of cancer cell 
formation by ACs from chokeberries in a dose dependent manner. 
Speculatively, the addition of berries to the diet of cancer patients could supress 
cancer cell growth, thereby reducing tumour size. 
 
Additionally, ACs possesses antioxidant properties (Xia et al. 2006; Mauray et 
al. 2010). Reactive oxygen species (ROS) including peroxides (H2O2) (Kallur et 
al. 2000), hydroxyls (-OH) (Ding et al. 2000) or singlet oxygen (1O2) (Karmat et 
al. 2000), can be produced by different pathways and reactions (St-Pierre et al. 
2006; Cedarbaum 2010; Quinlan et al. 2013; Hu et al. 2016; Zhenyukh et al. 
2018). Significantly high concentrations of ROS can lead to diseases such as 
prostate cancer (Bostwick et al. 2000) and cardiac disease (Tsutsui et al. 2001). 
ACs show more specificity to –OH radicals, due to the short life span (Ou et al. 
2012; Huang et al. 2016). Furthermore, ACs could stimulate gastro-intestinal 




fleshed potatoes, were shown to promote gastro-intestinal digestion (Liang et al. 
2011; Kubow et al. 2017). Thus, this demonstrates the benefits of berry and 
vegetable consumption. 
 
ACs has been reported to possess anti-inflammatory properties, acting in a 
similar manner to nonsteroidal anti-inflammatory drugs (NSAIDs) (Taverniti et 
al. 2014; Kuntz et al. 2015). NSAIDs suppress COX-1 and COX-2 (Griffin et al. 
2013; Carron et al. 2016), suppressing PG synthesis.  Conversely, NSAIDs do 
not inhibit Nuclear–Factor B (NF-κB) due to limited drug efficacy (Viegas et al. 
2011; Orlando et al. 2014; Nivanappa et al. 2016), whereas ACs have been 
shown to target NF-κB, reducing expression (Taverniti et al. 2014; Kuntz et al. 
2015). Furthemore,  a 2008 study demonstrated a mild inhibitory effect of ACs 
on CYP3A4 expression and reported by two other studies (Dreiseitel et al. 
2008; Srovnalova et al. 2014; Malhi et al. 2015). Whether other CYP450 
expression is affected by ACs is not clear, leading to the need of further 
research. 
 
5.2.2 Phase II and phase III detoxification of anthocyanins 
Consumed ACs are able to enter glucuronidation (Wu et al. 2002; Felgines et 
al. 2003; Kay et al. 2004). Consumption of ACs below the ADI has a low 
probability of toxic effects. It has been demonstrated that ACs may go through 
glucuronidation in some studies (Milbury et al. 2007; Woodward et al. 2011; de 
Ferrars et al. 2014; Mueller et al. 2017), Figure 5.4. The specific UGT for AC 
glucuronidation are not yet known, thus requiring further research. 





Organic anion polypeptide transporters (OATPs) are expressed on the BBB 
(Gao et al. 1999), liver (Kullak-Ublick et al. 2001) and intestine (Kobayashi et al. 
2003). Anthocyanins are substrates of OATP1B1 and OATP1B3 (Riha et al. 
2015) Anthocyanins have been reported by Riha et al. (2015) to increase 
OATP1B1 mRNA synthesis by approximately 60%. Conversely, OATP1B1 
mRNA synthesis is reduced by 25% approximately. This demonstrates that 
anthocyanins are potential inhibitors for OATP1B3 and induce OATP1B1 mRNA 
production. Thus, further research is necessary to determine effects of these 
induced alterations on other molecules. 
 
5.3 Butylated hydroxyanisole and butylated hydroxytoluene  
5.3.1 Butylated hydroxyanisole and butylated hydroxytoluene  
and cytochrome p450 
Butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) (Figure 
5.5) are used as food preservatives because of their antioxidant activities 
(Adamson et al. 1977; Ito et al. 1983; Ito et al. 1986; Goodman et al. 1990; 
Whysner et al. 1994; Yu et al. 1997). The ADI recommended for consumption is 
1.0 mg/kg bw/day for BHA, and 0-0.125 mg/kg bw/day for BHT. Potentially, 
consuming BHA and BHT may lead to toxic effects studies (Williams et al. 1991; 


















The potential toxicological effects of BHA and BHT have been explored in 
multiple animal and cell line studies (Williams et al. 1991; Grillo and Dulout 
1995; Grillo and Dulout 1995). Consumption of BHT over the recommended ADI 
may produce toxicological effects, including tumorigeneses (Williams et al. 
1991), genotoxic effects (chromosomal and DNA damage) (Grillo and Dulout 
1995), and heart rate suppression (Kaplan et al. 2003). Speculatively, if BHT is 
consumed over the ADI, these observed effects could occur in humans, 
contributing to the potential development of disease. 
 
The CYP2J2 gene is expressed in various tissues including the heart (Wu et al. 
1996), lungs (Zeldin et al. 1996), liver (Wu et al. 1996) and intestine (Zeldin et 
al. 1997). CYP2J2 primarily oxidises arachidonic acids (polyunsaturated acids 
found in phospholipids), but CYP2J2 can also detoxify BHT by an oxidative or 
hydroxylation reaction (Figure 5.6) (Yu et al. 1997; Thum and Borlak 2008; Lee 
and Murray 2010; Evangelista et al. 2013; McDougle et al. 2017). If BHT is 
detoxified by a hydroxylation reaction, hydroxy-tert-butyl (BHT-OH) is 
synthesised. Additionally, BHA has been identified to induce CYP2J2 
expression (Lee and Murray 2010). However, it is not extensively studied. This 
could be due to the ADI of BHA being higher than BHT and thus, requiring 
excess consumption for potential toxic effects to occur. 
 
Two main metabolites of BHT have been extensively studied, BHT-OH (Figure 
5.6) and BHT-QM (Figure 5.7). Both metabolites have the capabilities of 
inducing toxicological effects (DNA damage by cleavage), demonstrated in a 
number of studies (Nagai et al. 1993; Lewis et al. 1996; Oikawa et al. 1998). 
This genotoxic toxic effect induces cellular inflammation and subsequently, 



























Figure 5.7: Molecular structure of BHT-QM (Adopted from: U.S. National Library of 
Medicine 2019).  
 
5.3.2 Butylated hydroxyanisole and butylated hydroxytoluene 
and phase II metabolism 
Both BHT and BHA can be conjugated to UDP-glucuronate (UDP-glucuronic 
acid, UDP-GA) for detoxification. Alike to anthocyanins, the specific 
glucuronidation enzyme is not known. Additionally, BHT has been reported to 
reduce glucuronidation of APAP (Boindogurong et al. 2006; Tamura 2011), 
whilst BHA has been demonstrated to increase APAP glucuronidation (Hazelton 
et al. 1985; Gregus and Klaassen 1985). Evidently, further research is 
necessary to understand the role of BHT and BHA in glucuronidation of other 
xenobiotics, excluding APAP. Further exploration of the effects of BHA and BHT 





5.3.3 Butylated hydroxyanisole and butylated hydroxytoluene 
and phase III metabolism 
BHA and BHT are not substrates of any ABC transporters. BHA has been 
revealed to be a substrate of OATP1A1 and OATP2B1 (Cheng et al. 2005). 
OATP1As are coded by solute carrier family 22 member 6 (SLC22A6). 
OATP1As are expressed in the adult kidneys on the basolateral surface of the 
proximal tubes and on the choroid plexus in the brain (Lopez-Nieto et al. 1997; 
Pritchard et al. 1999; Ohtsuki et al. 2002). OATP2B1 is expressed within the 
liver (Kullak-Ublick et al. 200) and the intestines (Kobayashi et al. 2003). The 
transportation of BHT and BHA into the cell for phase I detoxification and phase 
II conjugation requires a Na+ gradient. A phase III transporter for detoxification 
has not been unearthed in the research available.  
 
Nrf2 is a basic leucine zipper (bZIP) protein transcription factor, regulating the 
expression of antioxidant protein coding genes such as PRDX6 (Chowdhury et 
al. 2009) and SOD1 (Woods et al. 2009). The presence of BHA and BHT 
stimulate ROS production by causing oxidative stress. In turn, the presence of 
ROS activates Nrf2 (Yuan et al. 2006; Jin et al. 2008; Lee and Murray 2010; 
Abdullah et al. 2012; Luo et al. 2015; Zheng et al. 2019). The activation of Nrf2 
reduces OATP1A1 mRNA production and conversely increases OATP2B1 
mRNA production (Cheng et al. 2005; Reisman et al. 2009; Aleksunes et al. 
2012). Thus, substrates of OATP1P1 transporters may have an altered fate. 
But, substrates of OATP1P1 which are also substrates of OATP2B1 may still be 
transported. Therefore, further study is recommended to explore the impacts of 












Clearly, the consumption of food additives can promote toxicological effects. If 
aspartame is consumed by a person with phenylketonuria, seizures and other 
complications may arise. Phenylketonuria is a result of a genetic mutation that 
reduces enzymatic activity of phenylalanine hydroxylase causing an 
accumulation of phenylalanine within the human body. Furthermore, the full 
effects of anthocyanins and the impacts anthocyanins have on the detoxification 
pathway remain for elucidation. Conversely,  butylated hydroxyanisole and 
butylated hydroxytoluene could be genotoxic leading to the potential of disease 
development along with suppressing glucuronidation activity of other molecules 
but, further exploration is needed. Thus, the consumption of food additives 





































Endogenous molecules could be synthesised from degradation of other 
molecules such as bilirubin (Lad et al. 2004; Jansen et al. 2010) (Section 6.1), 
hormones (Lin et al. 2006; Tsutsui et al. 2008) (Section 6.2 and 6.3) or 
neurotransmitters. However, abnormal concentrations of endogenous 
molecules can influence the development of abnormal physiological conditions, 
leading to disease development (Huang et al. 2013). Thus, this chapter 
discusses the detoxification of endogenous molecules and how alterations to 
genes within the detoxification can contribute to the onset of disease.  
 
6.1 Bilirubin  
6.1.1 Bilirubin synthesis and cytochrome p450 
Bilirubin, an insoluble molecule, is the end product of heme degradation (Lad et 
al. 2004; Jansen et al. 2010). Bilirubin synthesis requires two reactions (Figure 
6.1). Heme is firstly oxidised by heme oxygenase (HO), synthesising biliverdin 
(Lad et al. 2004; Reed et al. 2010; Lin et al. 2013; Lee et al. 2017). 
Subsequently, biliverdin is reduced to bilirubin by NADPH-dependent biliverdin 
reductase (BVR) (Jansen et al. 2010; Subhanova et al. 2013; van Dijk et al. 
2017). CYP1A1 or CYP1A2 is able to oxidise bilirubin as a degradation process, 
producing bilirubin oxidation products (Figure 6.2). Alternatively bilirubin can go 



























Figure 6.1: Enzymatic pathway for bilirubin synthesis. Bilirubin production occurs 
from heme degradation. Heme is first oxidised to biliverdin by heme oxygenase. 
Sequentially, biliverdin reductase reduces biliverdin to bilirubin. Heme HMBD ID:  
HMDB0003178. Biliverdin HMBD ID: HMDB0001008. Bilirubin HMBD ID: 
HMDB0000054. 
 
Figure 6.2: Oxidation of bilirubin to bilirubin oxidised products. The oxidisation 
reaction produces 4-methyl-5-oxo-3-vinyl-(1,5-dihydropyrrol-2-ylidene)acetamide and 
3-methyl-5-oxo-3-vinyl-(1,5-dihydropyrrol-2-ylidene)acteamide. The oxidised molecular 
structures are adopted from (Wurster et al. 2008). Bilirubin HMBD ID: HMDB0000054. 
 
6.1.2 Bilirubin and phase II glucuronidation 
Bilirubin is also glucuronidated and detoxified by the process of glucuronidation, 
via the conjugation of urine diphosphate-glucuronic acid (UDP-GA) to the -
COOH functional group by UGT1A1 (Figure 6.3). Bilirubin detoxification is 
affected by the UGT1A1*28 polymorphism, a genetic predisposition for Gilbert’s 
syndrome (Bosma et al. 1995; Ando et al. 1998). Gilbert’s syndrome is 
characterised by an accumulation of unconjugated bilirubin in the liver, leading 
to jaundice. Under normal physiological conditions, bilirubin concentrations can 




unconjugated bilirubin concentrations between 1mg/dL and 6mg/dL (Huang et 
al. 2013; Flores – Villalba et al. 2016). However, Gilbert’s syndrome should not 
























Figure 6.3: Bilirubin glucuronidation by UGT1A1. Once bilirubin is synthesised from 
heme degradation, bilirubin is subsequently glucuronidated. Bilirubin glucuronidation 
can either produce a monoglucuronide or a diglucuronide. Bilirubin HMDB: 
HMDB0000054; Bilirubin monoglucuronide HMDB accession number: HMDB0010332; 
Bilirubin diglucuronide HMDB accession number: HMDB0003325. Molecules in red 
present functional groups.  
 
UGT1A6 is a second glucuronidation enzyme for the detoxification of bilirubin. 
However, the detoxification of bilirubin in the presence of UGT1A16 is 1/10 
slower compared to UGT1A1 (Ciotti et al. 1998). Thus, UGT1A6 may act as a 
compensator if UGT1A1 is defective. 
 
Bilirubin 








6.1.3 Bilirubin and phase III transport 
OATP1B1 can transport endogenous molecules such as bilirubin (Passamonti 
et al. 2005; He et al. 2008; van de Steeg et al. 2012). Bilirubin is transported 
into liver cells for detoxification. Upon bilirubin glucuronide synthesis (Figure 
6.4) MRP1 transports bilirubin glucuronides from the cell for subsequent 
elimination. Additionally, bilirubin is also a substrate for OAT1B3 (König et al. 
2000; Hirano et al. 2004; Yamaguchi et al. 2006; Kindla et al. 2011; Zimmerman 
et al. 2013; Thomson et al. 2016; Alam et al. 2018). Mutations that affect 








Figure 6.4: Bilirubin detoxification pathway. Bilirubin molecules are transported into 
liver cells by OAT1B1 or OAT1B3. In the cell CYP1A1 or CYP1A2 biotransform bilirubin 
for glucuronidation by UGT1A1. Upon bilirubin glucuronide synthesis, MRP1 excretes 
bilirubin glucuronides from the cell for subsequent elimination. 
 
 
One mutation of the OATP1B1 alters the fate of bilirubin. rs71581941 
introduces a premature stop codon at amino acid position 580, a arginine to a 
stop codon (Arg580Ter). The consequence of this is a truncation of the 
transporter, producing a half TMD of TMD11 and TMD12, reducing the transport 
of bilirubin (Kim et al. 2007; van de Steeg et al. 2012; Kagawa et al. 2015; Yang 
et al. 2017). This mutation induces Rotor syndrome or Rotor type 
hyperbilirubinemia (OMIM #237450), causing jaundice. Rotor syndrome should 
not be confused with Gilbert’s syndrome. In Rotor syndrome the molecule 
coproporphyrin (decomposition of porphyrin molecules), is detectable in urine. 
Additionally, measuring the concentrations of both unconjugated bilirubin and 





The prevalence and allelic distribution of rs71581941 has is disproportionately 
associated with the Asian population (Table 6.1). A literature search was 
undertaken on allelic distributions. However, only one research article was  
found which primarily focusing on white Canadians (n=41), and reporting 1.4        
% of Canadians and 0.8% of white Europeans with the variant (Boivin et al. 
2010). An alternative search was conducted using two bioinformatics allele 
frequency databases on gnomAD and ExAC. ExAC was the only database 
which provided allele distribution, presented in Table 6.1. 
 














Additionally, a mutation in OATP1B3 also contributes to the development of 
Rotor syndrome. The mutation in OATP1B3 introduces a change at the amino 
acid position 253, changing arginine to a stop codon (Arg253Ter). The mutation 
causes an accumulation of bilirubin, which can also contribute to the 
development of Rotor syndrome (van de Steeg et al. 2012). The allelic 









East Asian 41 8646 1 0.004742 
Other 3 902 0 0.003326 




92 66476 0 0.001384 
European 
(Finnish) 
9 6574 1 0.001369 
African 10 10326 0 0.0009684 
South 
Asian 
11 16480 0 0.0006675 




knowledge to date on the association between Arg253Ter and Rotor syndrome, 
revealing a need for further research.  
 
MRP1 is not limited to transporting xenobiotics, medicinal and illicit drugs, but 
MRP1 can transport endogenous molecules such as bilirubin glucuronides 
(Figure 6.4). Bilirubin glucuronide transportation by MRP1 has been evidenced 
(Corich et al. 2009; Gazzin et al. 2011; Bigo et al. 2014; Wang et al. 2017). 
Bilirubin is a substrate of other ABC transporters ABCC2 (MRP2) (Toh et al. 
1999; Fouassier et al. 2002) and ABCC3 (MR3) (Bodó et al. 2003; Zelcar et al. 
2006). MRP2 and MRP3 could be compensator transporters if MRP1 is 
defective.  
 
6.2 Testosterone  
6.2.1 Testosterone synthesis  
Testosterone (Figure 6.5) is an androgen, synthesised in the Leydig cells 
(Mendelson et al. 1975; Chung and Allison 1979). Testosterone is synthesised 







Figure 6.5: Testosterone synthesis pathway. In the Δ5 pathway, cholesterol is 
cleaved to pregnenolone by CYP11A1 and converted to androstendiol by other 
biochemical reactions. Alternatively, Pregnenolone, 17α-hydroxypregnenolone or 
DHEA can be converted to progesterone, 17α-hydroxyprogesterone or adrenstendione, 
respectively within the Δ4 pathway and synthesised to testosterone and DHT.  
 
6.2.2 Testosterone and cytochrome P450 
Following synthesis, testosterone is secreted from the leydig cells into the 
peripheral circulatory system. Testosterone secretion is stimulated by the 
pituitary gland in response to gonadotropin-releasing hormone (GnRH) 
(Mongkonpunya et al. 1975; Happ et al. 1978). CYP3A4 hydroxylates 
testosterone, producing the metabolite 6-β-hydroxy testosterone (6β-OH-
testosterone) (Figure 6.6) (Lin et al. 2006; Sivertsson et al. 2010; Patil et al. 
2014; El-Sayed et al. 2016). Additionally, CYP3A5 has been reported to 




al. 2015; Smith et al. 2018). CYP3A4 is the major CYP450 for testosterone 











Figure 6.6: Phase I detoxification of testosterone.  
 
A CYP3A5 polymorphism (CYP3A5*3) affects phase I preparation of 
testosterone. CYP3A5*3 is a result of a nucleotide mutation, G22893A, 
generating a cryptic splice site forming exon 3B. Consequently, the generation 
of exon 3B introduces a premature stop codon after amino acid position 102 
(Kuehl et al. 2001; Fröhlich et al. 2004; Canonico et al. 2008). The premature 
stop codon produces a non-functional variant, causing protein truncation. 
Therefore, phase I preparation by CYP3A5*3 promotes an accumulation of 
testosterone that has not been hydroxylated for phase II conjugation. 
Sequentially, the accumulated testosterone may promote abnormal cellular 
growth leading to tumour development, leading to prostate cancer (Stanbrough 
et al. 2006; Pierorazio et al. 2010). 
  
Early diagnosis of prostate cancer increases survival. Generally, prostate 
cancer affects middle aged men and older however, younger men can also be 
affected. The risk of developing prostate cancer is approximately 2 to 4 times 
higher in black men (Jones and Chinegwundoh 2014; Machiori et al. 2016). 
Conversely, white men have a lower risk of developing prostate cancer. The 








6.2.3 Testosterone and phase II 
Testosterone is another molecule that requires glucuronidation, catalysed by 
UGT2B17 (Ekström et al. 2012; Zhu et al. 2015; Martín-Escudero et al. 2019), 
Figure 6.7. Testosterone glucuronidation prevents an excess accumulation of 
active testosterone. There are other UGTs which have the capabilities of 
testosterone glucuronidation such as UGT2A7 (Sten et al. 2009; Jenkinson et 
al. 2012; Wang et al. 2014; Basit et al. 2018). Alternatively, UGT2B15 can 
glucuronidate testosterone. Thus, UGT2B15 and UGT2A7 may act as 
compensators for UGT2B17.  
Figure 6.7: Phase II detoxification of testosterone  
 
The UGT2B17 gene can be deleted, causing problems with glucuronidation of 
testosterone. If the gene deletion is heterozygous, there could be reduced 
glucuronidation activity towards testosterone. Studies have reported that 
UGT2B17 deletion is a potential genetic predisposition for prostate cancer 
(Gallagher et al. 2007; Bai et al. 2010; Kpoghomou et al. 2013; Urashima et al. 
2015). However, as discussed above there are potential gene compensators 
which may reduce the risk of prostate cancer (Sten et al. 2009; Jenkinson et al. 
2012).  
 
UGT2B15*2 (rs1902023) polymorphic variant (Asp85Tyr; exon 1), upregulates 
gene expression. Upregulated expression of UGT2B15*2 may also act as a 
predisposition for prostate cancer (Ahern et al. 2011; Strahm et al. 2013; 
Romero-Lorca et al. 2015). This is due to increased glucuronidation activity, 
reducing the amount of biologically active testosterone. Thus, reduced presence 




four different studies have associated glucuronides with prostate cancer 
associated with genetics (Appendix 2 and Table 8.5) and only one study has 
reported a glucuronide associated with prostate cancer and lifestyle (Section 
8.3.4.2).  
 
In all prostate cancer a phase II coding gene for a glutathione conjugating 
enzyme, GSTP1, is hypermethylated (Millar et al. 1999; Song et al. 2002; 
Rosenbaum et al. 2005). Multiple studies have reported that the GSTP1 gene is 
hypermethylated (Song et al. 2002; Enokida et al. 2005; Bryzgunova et al. 
2008; Delgardo-Cruzata et al. 2012; Zhang et al. 2015; Hendriks et al. 2018). 
Clearly, this is one of the most extensively studied epigenetic mechanism of 
prostate cancer. Thus, the methylated GSTP1 could also be a potential 
biomarker for the identification of prostate cancer. Furthermore, the methylation 
of GSTP1 prevents gene expression for GSTP1 protein and therefore, toxic 
molecules could accumulate within the prostate which may contribute to the 
development and severity of prostate cancer.  
 
Alternatively, testosterone can be sulphated which also aids in the elimination of 
testosterone from the body. Testosterone can be sulphated by SULT1A1 
(Sparks et al. 2004) and SULT2A1 (Schulze et al. 2013), as an alternative 
phase II conjugation process. Upon the synthesis of testosterone sulphate 
metabolites, the inactive sulphate metabolite are subsequently eliminated via 
urination (Gonzalo-Lumbreras et al. 2003; Saudan et al. 2006; Piper et al. 
2010).   
 
5.2.4 Testosterone and Phase III transport  
Testosterone in phase III is secreted from the testes, and prevented from 
penetrating the blood-testis barrier (BTB) by two transporters, MRP1 and MRP4 
(Qian et al. 2001; Bart et al. 2004; Sivils et al. 2010; Dankers et al. 2013; 
Morgan et al. 2015). MRP1 and MRP4 actively transport testosterone from the 
leydig cells after synthesis. However, the link between these transporters and 
testicular cancer is not clear. Altered expression of ABCC1 (MRP1) and ABCC4 




In prostate cancer ABCC1 and ABCC4  are highly expressed (Zalcberg et al. 
2000; Sullivan et al. 2000; Cai et al. 2006). The increased expression impedes 
drug-based cancer treatment. It is unclear whether over-expression is 
influenced by a mutation, or whether it is a natural molecular characteristic in 
prostate cancer. Nevertheless, studies have reported that p53 is able to 
regulate ABCC1 (Thottassery et al. 1997; Sullivan et al. 2000), by binding to the 
promotor region of the gene. This implies that expression of ABCC1 alters 
expression which could potentially contribute to ABCC1 expression. Therefore, 
contributing to drug-based chemo-resistance.  
6.3 Oestrogen  
6.3.1 Oestrogen synthesis  
Oestrogen is the primary sex hormone in females (Bowen et al. 2011). 
Oestrogen is an umbrella term for three specific hormones: oestradiol (Figure 
6.8) and oestrone (Figure 6.8) and oestriol (Figure 6.9). Oestrone and oestradiol 
have functional roles in the reproductive menstrual cycle, with oestrone 
influencing the onset of the cycle (Sipavičiené et al. 2015), and oestradiol 
regulating ovulation (Wang et al. 2018). Oestriol has been observed to keep the 
uterus in a quiescent (resting) state to prevent early labour from occurring 
(Cohen 1985). Oestrogen is synthesised from cholesterol cleaved by CYP11A1 
(CYP450scc), producing pregnenolone (Figure 6.8) (Tsutsui et al. 2008; Mast et 
al. 2011; Fan and Papadopoulos 2013). Once pregnenolone is synthesised, 
several intermediate molecules can be produced by different biochemical 












Figure 6.8: Oestrogen synthesis pathway. Hormones in red present 
mineralocorticoids. Hormones in blue present glucocorticoids. Hormones in green 








Figure 6.9: Molecular structure of oestriol.  
 
6.3.2 Oestrogen and cytochrome P450 
To ensure there is not an accumulation in active oestrogen, oestrogen is 
hydroxylated, by CYP1A2 (Hong et al. 2004) and CYP3A4 (Cheng et al. 2001), 
Figure 6.10. The discussion will be based on oestradiol as the primary 
oestrogen hormone. The kinetic parameters for CYP1A2 in the presence of 
oestradiol have been reported with a Km of 58 ± 4 µM and a Vmax of 0.7 ± 0.2 
min-1. Whilst, CYP3A4 has kinetic parameters where Km has been reported to 
be 75 ± 18 µM and a Vmax of 0.4 ± 0.2 min




demonstrates that CYP1A2 has a higher affinity for oestradiol. However, the 
rate of reaction (Vmax) is higher for CYP3A4 compared to CYP1A2. In this case 











Figure 6.10: Phase I hydroxylation of oestradiol.  
 
A molecular characteristic of breast cancer is abnormal oestrogen 
concentrations (Brinton et al. 1986; Colditz et al. 1990; Törnberg and 
Carstensen 1994). Similarly to testosterone, an accumulation of oestrogen 
leads to promotion of cellular growth. Alternatively, decreased oestrogen 
prevents cellular growth. In both situations cellular mutations and 
tumorigeneses could occur to compensate for the local environment. 
Additionally, a polymorphic CYP1A2 may influence the amount of oestrogen 
present (T1545C, rs71581941). rs2470890 has been associated with breast 
cancer in some studies (Anderson et al. 2012; Vukovic et al. 2016; Bai et al. 
2017). However, the molecular function of the polymorphism is not known. 
 
The CYP3A4*1b polymorphism has been observed in breast cancer. However, 
it is unclear whether CYP3A4*1b influences breast cancer. A number of studies 
reported a lack of functional association of CYP3A4*1b with breast cancer 
development (Spurdle et al. 2002; Chu et al. 2007; Fernández-Santander et al. 
2013; Abdullah et al. 2016; Veiga et al. 2018). Thus, further research is required 





6.3.3 Oestrogen and phase II conjugation 
Similarly to testosterone, oestrogen can be glucuronidated by UGT2B17 (Hirata 
et al. 2010) or UGT2B15 (Hu et al. 2016), Figure 6.11. However, the 
UGT2B15*2 polymorphism also affects oestrogen glucuronidation. The effect of 










Figure 6.11: Phase II conjugation of oestradiol.  
 
In addition to the association with prostate cancer, UGT2B15*2 may be 
implicated in breast cancer. This has been reported to be due to decreased 
function (Park et al. 2006; De Smith et al. 2008; Sun et al. 2012; Divakaran et 
al. 2014). Thereby, reduced glucuronidation activity of oestrogen may leave 
oestrogen concentrations to accumulate which could contribute to the 
development of breast cancer. The allele frequencies of UGT2B15*2 has been 


























Table 6.2: Human allele frequency distribution of UGT2B15*2  
 




























NS*: Not specified 
 
A deletion variant polymorphism of UGT2B17 is also associated with a 
predisposition for breast cancer (Park et al. 2006; Eskandari-Nasab et al. 2012). 
Several studies have reported on the effects of this polymorphism (Park et al. 
2006; Eskandari-Nasab et al. 2012; Urashima et al. 2015; Packard et al. 2018). 
The UGT2B17 gene deletion may causes an accumulation of oestrogen, 
promoting cellular growth in the breast tissue (Ménard et al. 2009). Sequentially, 
this promotion of cellular growth can contribute to the development of breast 
cancer. Thus, three studies have reported three glucuronides that could be 
produced in breast cancer (Appendix 2 and Table 8.6). Research to date on 
breast cancer has not elucidated potential glucuronides and lifestyle influences 
for breast cancer. 
 
Population Subject (n) Allele frequency 






117 0.41 NS* 
 





0.79 (Toide et al. 
2002) 
 
77 0.49 NS* (Riedy et al. 
2000) 







273 0.55 NS* (Riedy et al. 
2000) 
202 0.55 NS* (Lampe et al. 
2000) 
100 0.53 NS* (Ménard et al. 
2009) 
54 0.56 0.40 (Court et al. 
2004) 
178 0.58 NS* (Hajdinjak et 
al. 2004) 




41 0.44 NS* (Court et al. 
2017) 
Hispanic 187 0.37 NS* (Riedy et al. 
2000) 





Similarly, in breast cancers, GSTP1, is also methylated (Lasabova et al. 2010).  
The methylation of GSTP1 has also been confirmed in later studies (Miyake et 
al. 2013 Fang et al. 2015; Kostovska et al. 2018). Evidently, the methylation of 
GSTP1 could also be a potential biomarker for breast cancers along with 
screening for the potential glucuronide that are may be associated with breast 
cancer.    
 
Oestrogen can be sulphated for detoxification as an alternative to 
glucuronidation (Sparks et al. 2004; Furimsky et al. 2007). Thus, upon the 
detoxification via sulfation, oestrogen sulphate metabolites are eliminated from 
the body. Thereby, sulphation is an alternative phase II detoxification process 
for oestrogen.   
 
6.3.4 Oestrogen and phase III transportation 
ABCG2 codes for the BCRP transporter component molecules, producing a 
half-transporter. A half-transporter is comprised of six transmembrane domains 
(TMDs) (Xu et al. 2004; Tusnády et al. 2006) (Figure 6.12). As a half 
transporter, BCRP is non-functional and requires dimerisation to occur for 
functionality (Kalinina et al. 2009; Lee and Levin 2015). Homodimerisation is the 
bonding of two identical protein chains (Kalinina et al. 2009; Rodríguez and 
Gutiérrez-de-Terán 2012; Liu et al. 2015; Guo et al. 2017; Maio et al. 2019), 
differing from the attachment of two different protein chains in 
heterodimerisation (Lee and Levin 2015; Cai et al. 2017; Cao et al. 2019). The 
BCRP transporter has been recognised as a homodimer transporter (Doyle et 
al. 1998; Kage et al. 2001; Henriksen et al. 2005; Leimanis and Georges 2007; 
Shigeta et al. 2010; Ogura et al. 2015). The functional dimer BCRP transporter, 



















Figure 6.12: Predicted BCRP transmembrane topological structure. Predicted 
number of transmembrane domains using TMHMM v. 2.0 (TMHMM 2019), Accession 
number: AAC97367.1. Blue line presents TMDs within the cell, pink line presents TMDs 
outside of the cell. 
 
BCRP transporters, in addition to their expression in the breast, are also 
expressed within the gastrointestinal tract (Gutmann et al. 2005), placenta 
(Wang et al. 2006) and the lungs (Nickel et al. 2017). The BCRP transporter is 
associated with oestrogen due to the oestrogen response element (ERE) found 
within BCRP (Ee et al. 2004; Lowery et al. 2009). The ERE comprises a 
palindromic sequence, putative (Pu)GGTCA, within the gene promoter region, 
induced by oestradiol. The presence of oestradiol promotes mRNA production 
(Ee et al. 2004; Wang et al. 2006; Day et al. 2009; Wu et al. 2012; Qian et al. 
2015; Maddox et al. 2018). Receptors such as oestrogen receptor alpha and 
beta (ERα and ERβ), can bind to the ERE, to promote BCRP expression 
induced by oestrogen molecules. Therefore, increased oestrogen molecules, 
promotes an up-regulation in BCRP expression and consequently follows onto 










Endogenous molecules are synthesised within the body from molecule 
degradation to the synthesis of hormones and neurotransmitters. Alterations to 
the concentrations of endogenous molecules can lead to the development of 
disease that is influenced by gene variants. Gilbert’s syndrome is a result of 
increased bilirubin concentrations due to the UGT1A1*28 variant which cannot 
glucuronidate bilirubin. Thus, jaundice can be observed and furthermore, 
individuals with UGT1A1*28 could also be at a higher risk of hepatotoxicity if 
acetaminophen is consumed.  Altered testosterone concentration may 
contribute to the development of prostate cancer. This is because the variant 
UGT2B15*2 has increased gene expression and therefore, reducing 
testosterone concentrations,  which could lead to the development of prostate 
cancer. Alternatively, the UGT2B17 deletion genotype, increases testosterone 
concentration. Thereby, the increased concentrations promotes abnormal 
cellular growth leading to the potential development of prostate cancer. Alike to 
oestrogen altered concentrations can also be pathogenic. The same variants, 
UGT2B15*2 and UGT2B17 deletion genotype, can be observed in breast 
cancers. Therefore, clearly patients with a disease such as cancers should be 
screened for other polymorphisms alongside the known disease causing 












































Xenobiotics are foreign molecules that are not naturally produced within the 
human body (Croom et al. 2012) Xenobiotics can come from a diverse range of 
sources such as the consumption of overcooked meats, smoking and pollution. 
All of which are detoxified via the detoxification pathway. As discussed in 
previous chapters and the fate of molecules in the presence of gene variants, 
the fate of xenobiotics are also influenced by gene variants as discussed in this 
chapter.   
 
7.1 PhIPs  
7.1.1 Introduction to PhIPs and phase I detoxification of PhIPs 
Xenobiotics are molecules from sources outside of the human body. These 
molecules can be associated with cancer development, such as 2-Amino-1-
methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) (Figure 7.1). PhIPs is a type of 
heterocyclic amine (HCA) molecule, produced from overcooked meats and fish 







Figure 7.1: The molecular structure of PhIP  
 
PhIP influences cancer development by exerting carcinogenic effects in the 
colon and mammary glands. Multiple studies reported induction of cellular 
proliferation at low doses of PhIPs (Zhu et al. 2005; Gooderham et al. 2007). 
This is through the stimulation of the MAP/ERK phosphorylation signal 
transduction pathway (Zhu et al. 2005; Gooderham et al. 2007). Additionally, 
PhIP was observed to inhibit the G1 phase of the cell cycle preventing mitosis 
(Zhu et al. 2005; Gooderham et al. 2007), leading to potential tumorigenic 
mutations. Whereas a later study reported that the presence of PhIP molecules 
can increase the number of cells within G1 phase of the cell cycle (Mimmler et 




also lead to cellular mutations and potential disease development. Other 
carcinogenic effects include the formation of PhIP DNA adducts (Turteltaub et 
al. 1993; Ghoshal et al. 1995; Josyula et al. 1998). DNA adducts are formed by 
the binding of a DNA segment to a carcinogenic molecule. This is due to the 
bioactivation by CYP1A1 or CYP1A2 by a hydroxylation reaction, synthesising 
an active metabolite, N-hydroxy-PhIP (N-OH-PhIP) (Huber et al. 1997; 
Galijatovic et al. 2001; Malfatti et al. 2005), Figure 7.2. The formation of DNA 




Figure 7.2: Phase I detoxification of 2-Amino-1-methyl-6-phenylimidazo(4,5-
b)pyridine. This phase I reaction produces the metabolite N-OH-PhIP. 
 
p53 protein tumour suppressor coined as the “guardian of the genome”, is 
stimulated by cellular damage and oxidative stress. p53 activation induces the 
apoptotic pathway, preventing cellular mutations and development of cancerous 
cells. However, p53 is highly susceptible for degradation,  therefore the 
vulnerability of p53 could be a factor in disease development (Ozeki et al. 2011; 
Zhang et al. 2014; de Stephanis et al. 2018). p53 degradation occurs through a 
cascade of events (Figure 7.3) involving attachment of mouse double minute 2 
homolog (MDM2, E3 ubiquitin protein ligase). E3 ligase binds to p53 at the 
target recognising domain, enabling an E2 conjugating enzyme to binds to the 
E2 interacting domain of E3. Subsequently, E2 attaches ubiquitin (Ub) 
molecules to p53. As polyUb chains act as a marker for degradation by 















Figure 7.3: The pathway for p53 degradation. A cascade of events involving 
ubiquitinin (Ub), Ub activatior protein E1, congugating enzyme E2 (grey circle), and 
MDM2 ligase E3 (black rectangle) acting upon p53 (orange circle). E1 forms a 
ubiquitin-thioester (Lee and Schindelin 2008; Xu et al. 2010) leading to transfer of the 
thioester-linked Ub to a cysteine residue in E2. E3 MDM2 ligase binds p53 at the target 
recognising domain (orange rectangle), enabling E2 binding to the interaction domain 
(grey rectangle). E2 conjugates Ub to lysine residues in p53 for degradation (David et 
al. 2010; Cohen et al. 2013). Subsequently, p53 is degraded by a proteosome (blue 
oval) and free Ub is formed, and recycled. 
 
DNA adducts could be used as a marker for cancer, due to PhIP accumulation 
leading to dose-dependent adduct development and potential influences in 
cancer development. Thus, the number of DNA adducts could be measured 
based upon the amount of meat consumed (Tang et al. 2007; Singh et al. 2010; 
Tang et al. 2013; Hemeryck et al. 2016; Durmus et al. 2019). Concluding this, 
individuals who consume large amounts of meat could be at a higher risk of 
developing prostate and colon cancer, compared to individuals who may 
consume only small amounts of meat (Aykan 2015; Saliba et al. 2019).  
 
7.1.2 Phase II conjugation of PhIPs  
After phase I preparation synthesising the metabolite N-OH-PhIP, subsequent 
glucuronidation by UGT1A10 occurs (Figure 7.4) (Malfatti and Felton 2001; Xie 
et al. 2003). PhIP glucuronidation by UGT1A10 has also been confirmed in later 
studies (Malfatti et al. 2005; Girard et al. 2008; Tang et al. 2013; Rogers et al. 
2016; Lin et al. 2018), which demonstrate UGT1A10 is the major UGT1A for 




metabolites for detoxification. The UGT1A1*28 polymorphism also alters the 
fate of N-OH-PhIP, due to reduced gene expression, promoting an 
accumulation of PhIP adducts (Girard et al. 2005). PhIP adducts are 
carcinogenic and therefore promote tumorigenesis (Girard et al. 2005; 
Cotterchio et al. 2008; Tang et al. 2013; Xiao et al. 2016). Thus, individuals with 
the UGT1A1*28 could be at a higher risk of cancer. But, there are other UGTs 
able to glucuronidate N-OH-PhIP. These other UGTs include UGT1A9 (Yueh et 
al. 2001), UGT1A6 (Malfatti and Felton 2001) and UGT1A4 (Dellinger et al. 
2007). Clearly, UGT1A9, A6 and A4 may act as compensators for both 











Figure 7.4: Phase II conjugation of a PhIP molecule. N-OH-PhIP glucuronide 
structures are adopted from (Stillwell et al. 2002). 
 
7.1.3 Phase III transport of PhIPs 
BCRP has capabilities of transporting xenobiotics, such as PhIPs, and 
medicinal drugs into the bile or urine for elimination (Dietrich et al. 2004; 
Cerveny et al. 2006; Enokizono et al. 2008; Graber-Maier et al. 2010; Vlamming 
et al. 2014; Shi et al. 2017). BCRP transporters prevent the carcinogenic effects 
exerted by PhIP by transporting PhIP molecules and metabolites into the bile or 
urine for elimination. To conclude this, the consumption of overcooked meats 
can lead to the formation of PhIP-DNA adducts within the colorectal region of 
the human body. The presence of the adducts within the colorectal region can 






7.2.1 Ethanol  overview and phase I detoxification 
Ethanol  (Figure 7.5), commonly known as alcohol, is consumed for a variety of 
purposes. The consumption of alcohol often causes a common side effect, 
veisalgias (“hangovers”). This is influenced by different factors such as how 
much alcohol is consumed and ethnicity (Wetherill and Fromme 2009; Prat and 
Adan 2011; Penning et al. 2012). For instance, approximately 50% of the Asian 
population cannot consume alcohol, due to a missense mutation in the ALDH 
gene which codes for ALDH2*2 (E487K) (Goedde et al. 1992).  
 
Upon the consumption of alcohol ethanol molecules induces CYP2E1 
expression (Wolf et al. 2007; Cedarbaum 2011; Jin et al. 2013). Ethanol 
preparation in phase I of the detoxification pathway is the minor pathway for 
ethanol detoxification in the microsomal ethanol oxidising system (MEOS) 
system (Figure 7.5). Respectively, CYP2E1 oxidises ethanol in the presence of 
NADH, to acetaldehyde (Zhong et al. 2014; Xu et al. 2017). After subsequent 
synthesis of acetaldehyde, NAD+-dependent aldehyde dehydrogenase 
(ALDH2) oxidises acetaldehyde to acetone (Suprun et al. 2006; Quintanilla et 
al. 2007; Jelski et al. 2011; Choi et al. 2015). Acetone is subsequently excreted 










Figure 7.5: Microsomal ethanol oxidising system. In the cytoplasm ADH is 
constitutively expressed for the detoxification of ethanol to acetaldehyde. Alternatively, 
in the liver microsomes, CYP2E1 could be induced to synthesise acetaldehyde from 





A variant of CYP2E1 has been reported to cause a mutation in the 5’ flanking 
region. This is nucleotide mutation C1055T (rs2031920) (Hayashi et al.1991; 
Watanabe et al.1994). The variant is thought to contribute to alcohol 
dependence along with ALDH2. But, the mechanisms of CYP2E1*5B and 
ALDH2 is not clear (Kim et al. 2010; Webb et al. 2010). Therefore, further 
investigation is necessary to understand how both genes contribute to alcohol 
dependence. Nevertheless, the CYP2E1*5B, was found to be associated with 
the Asian populations (Tang et al. 2010; Shahriary et al. 2012; Guaoua et al. 
2014). The allele distributions are presented in Table 3.3. 
 
7.2.2 Phase II detoxification of ethanol 
The MEOS system is the primary detoxification pathway for ethanol. Ethanol 
can also go through glucuronidation (Helander et al. 2009; Reisfield et al. 2011; 
Saabi et al. 2013), the minor pathway for ethanol detoxification. Glucuronidation 
of ethanol synthesises ethyl glucuronides, catalysed predominantly by UGT1A1 
and UGT2B7 (Figure 7.6) (Foti and Fisher 2005; Halter et al. 2007; Høiseth et 
al. 2010; Lostia et al. 2013; Stachel and Skopp 2016; Małkowska et al. 2018). 
Thereby, ethanol can be detoxified by two different processes: the MEOS 
system in Figure 7.5 or glucuronidation.  
 
Figure 7.6: Phase II glucuronidation of ethanol.  
 
Ethanol can interfere with APAP detoxification, particularly in individuals who 
abuse alcohol, by promoting liver damage. In addition to glucuronidation, 
ethanol molecules can be detoxified via GSH conjugation, depleting GSH 




Guidot 2010; Chitty et al. 2013; Chen et al. 2017). Due to this, individuals who 
take APAP are potentially at higher risk of liver failure. The reduction in GSH 
molecules allow APAP to interact with molecules in the liver, inducing liver 
failure. Thereby, impairing the detoxification of other molecules. 
 
7.2.3 Phase III transportation of ethanol 
In phase III, ethanol molecules are substrates for ABCA1 transporters, 
increases  the transportation of cholesterol molecules (e Silva et al. 2000). 
Cholesterol itself has several vital roles including normal development of the 
brain (Hanaka et al. 2000; Guizetti et al. 2007). In the presence of alcohol 
abuse, offspring of an alcoholic user are likely to produce offspring with foetal 
alcohol syndrome (FAS) due to cholesterol transport interference from alcohol 
consumption (van der Gaag et al. 2001; Beulens et al. 2004; Guizzetti et al. 
2007; Lesená et al. 2010; Zhou et al. 2014). ABCG1 also transports cholesterol 
however, the full impacts of alcohol on cholesterol transport by ABCG1 requires 
elucidation (Zhou et al. 2014). 
 
A mutation in ABCG1 can promote the onset of gout (Phipps-Green et al. 2010; 
Li et al. 2015; Duong et al. 2019). Gout is caused by excess uric acid (Villa et al. 
1958; McCarty and Hollander 1961; Scott et al. 1964). The excess uric acid 
causes crystals to form and accumulate within the joints, presenting as lumps 
(Gaber et al. 2013; Onuma et al. 2014). The mutation contributing to alcohol 
induced gout is rs72552713. rs72552713 introduces a premature codon at 
Q216 (Gln126Ter, Q126X) and has been reported to increase uric acid 
concentrations (Ichida et al. 2012; Matsuo et al. 2016; Stiburkova et al. 2019). 
Additionally, rs72552713 is found to be disproportionately associated with the 
eastern Asian population (Table 7.1) as discussed in studies (Matsuo et al. 
2009; Hamajimi et al. 2011; Matsuo et al. 2014 Matsuo; et al. 2016; Nakamura 
et al. 2018). The association of alcohol to gout and the non-functional ABCG1 


















East Asian 97 19912 0 0.004871 
Other 3 7172 0 0.0004183 
Latino 1 35276 0 0.00002835 
African 0 24938 0 0.000 
Ashkenazi Jewish 0 10350 0 0.000 
European (Finnish) 0 25042 0 0.000 
European (non-
Finnish) 
0 128514 0 0.000 
South Asian 0 30504 0 0.000 
 
7.3 Nicotine 
7.3.1 Nicotine and cytochrome p450  
Cigarette smoking is considered a common practice (Gonzalez-Quintela et al. 
2008). However, there are negative consequences associated with smoking. 
The carcinogenic effects of nicotine (Figure 7.7) remain unclear, in vitro studies 
demonstrate genotoxic effects (Ginzkey et al. 2013; Ginzkey et al. 2014a; 
Ginzkey et al. 2014b). However, smoking can lead to tumour development. A 
2018 study compared the carcinogenic effects of vaporised nicotine from 
electronic (e) cigarettes to tobacco smoking, concluding that nicotine from e-
cigarettes is less carcinogenic, but still has potential for carcinogenic effects 
(Stephens et al. 2018). The presence of nicotine stimulate the activation of 
CYP1A1 and CYP1A2 for phase I preparation (Anttila et al. 2001; Mohammed 
and Shervington 2008; Hukkanen et al. 2011; Ezzeldin et al. 2017). However, a 
CYP1A2 polymorphism affects the detoxification process of nicotine (Sachse et 











Figure 7.7: The molecular structure of nicotine. 
 
CYP1A2*1C is a result of the nucleotide mutation G3858A, but the functional 
properties are not clear. It is thought that the polymorphism causes loss of 
function (LOF) (Nakajima et al. 1999). Conversely, later studies demonstrate 
that in individuals who smoke, who have the CYP1A2*1C polymorphism, the 
detoxification of nicotine is increased (Sachse et al. 2003; Katoh et al. 2010; 
Khono et al. 2013; Xiong and Li 2017). Thus, smokers who have the 
CYP1A2*1C polymorphism may have a reduced chance of cancer development 
due to the increased expression for nicotine detoxification. The discrepancies in 
the function of Allele frequency studies report that CYP1A2*1C is associated 
with the Asian population (Table 7.2). 
 
Table 7.2: Frequency distribution of CYP1A2*1C 
 
 




7.3.2 Nicotine and Phase II and phase III 
Nicotine is detoxified in phase II by glucuronidation, catalysed by UGT2B10 or 
UGT2B17. UGT2B10 and UGT2B17 glucuronidation activity towards nicotine 
has been observed in various studies (Lazarus et al. 2005; Chen et al. 2007; 
Chen et al. 2010; Murphy et al. 2014; Ware et al. 2016) (Figure 7.8). Two 
polymorphisms of UGT2B10 have been reported to alter the fate of nicotine: 











Figure 7.8: Phase II conjugation of nicotine for detoxification. The 




rs61750900 (UGT2B10*2) is a missense mutation causing the amino acid 
change Asp67Tyr. The polymorphism is thought to act as a predisposition for 
lung cancer because rs61750900 is non-functional and therefore nicotine 
glucuronidation does not occur (Berg et al. 2010; Murphy et al. 2014; Taghavi et 
al. 2017). Therefore, the presence of unconjugated nicotine in the urine can be 
observed (Matsumoto et al. 2013; Wassenaar et al. 2015). Subsequently, long-
term exposure in affected individuals may influence lung cancer onset 
(Sheppard et al. 2000; Chu et al. 2004; Le Marchand et al. 2008). Unconjugated 
nicotine in the urine may signify predisposition to lung cancer, however further 
research to determine the significance is needed. The allele distribution of 





Table 7.3: Human allele frequency distribution of rs61750900 
NS*: Not specified  
 
7.3.3.2 rs2942857   
rs2942857  is another SNP which affects the glucuronidation activity of 
UGT2B10 (Murphy et al. 2014). rs2942857 causes a splice variant, reducing 
glucuronidation activity. The splice variant causes an alteration between intron 2 
and exon 3, disrupting the splicing acceptor site (Patel et al. 2015; Chen et al. 
2016; Labriet et al. 2018). The variant is thought to predominantly affect those 
of African-American descent (Patel et al. 2015), potentially disposing the carrier 
to lung cancer (Murphy et al. 2014; Patel et al. 2015; Murphy et al. 2018), 
because of reduced glucuronidation activity. A search was undertaken on EVS 
for rs2942857, however it was unavailable. Additionally, rs2942857  was 
searched for on gnomAD and ExAC databases for allele distributions and no 
results were found. Evidently, further work is necessary to understand which 
ethnic backgrounds are affected by the polymorphism. Additionally, further 
studies are necessary to reveal the relationship between rs2942857  and lung 
cancer. 
 
In smokers, the presence of nicotine suppresses both ABCA1 and ABCG2 
expression, particularly in individuals with coronary artery disease (CAD) and 




chance of pulmonary emphysema. The presence of nicotine reduces 
cholesterol transport by ABCA1 and ABCG2 and leads to an accumulation in 
cholesterol foam cell formation (Bochem et al. 2013; Song et al. 2015; Tao et al. 
2017). Consequently, foam cells can develop to plaques, blocking arteries. As a 
result, this acts as a predisposition to the development of CAD and CHD. 
Additionally, several inflammatory markers related to smoking can be observed 
such as: fibrinogen (Dahl et al. 2001), tumour necrosis factor alpha (TNF-α) 
(Bolton et al. 2004), cytokines (Wojcik et al. 2008) and C-reactive proteins 
(Şahin and Aslan 2018). All of which can be influenced by mutation in ABCA1 
acting as a predisposition for CAD and CHD development.  
 
ABCA1 rs2230806 is a genetic predisposition for CHD, causing an Arg219Lys 
(R219K) mutation (Villard et al. 2013; Cyrus et al. 2016; Wang et al. 2019). 
CHD is associated with an accumulation in low-density lipoprotein (LDL) 
cholesterol. The accumulation of LDL cholesterol suggests rs2230806 reduces 
function. Studies have reported that rs2230806 influences the severity of CHD 
(Cenarro et al. 2003; Kyriakou et al. 2007; Doosti et al. 2010; Zargar et al. 2013; 
Ghaznavi et al. 2018). Furthermore, it has been postulated that rs2230806 in 
the Asian population may serve as a protective mechanism from high-density 
lipoprotein (HDL) cholesterol, but not in Caucasians (Liu et al. 2015). This 
suggests that gene polymorphisms may function differently in different 























7.4  Polycyclic aromatic hydrocarbons 
7.4.1 Polycyclic aromatic hydrocarbons and cytochrome p450  
Polycyclic aromatic hydrocarbons (PAHs) (Figure 7.9) are organic pollutant 
molecules which come from a number of environmental sources such as: grilled 
food (Lee et al. 2016), the burning of organic matter (Samburova et al. 2016), 
and smoking (Wang et al. 2016). If PAHs enter the body CYP450s bioactivate 
PAH molecules, by which the active toxic PAH metabolites able to elicit 
toxicological effects. For instance, the presence of pyrene molecules in the liver 
stimulate the activation of CYP1A1 (Pandey et al. 2006), CYP1B1 (Šulc et al. 
2016) and CYP3A4 (Juschyshyn et al. 2005).  If pyrene molecules are 
hydroxylated by CYP3A4 (Figure 7.9), hydroxypyrene metabolites are 
synthesised (Jushchyshyn et al. 2005; Ciarrocca et al. 2014).  
 










African 6512 10402 2077 0.626 
East Asian 3846 8628 887 0.4458 
South Asian 6078 16510 1120 0.3681 
Other 306 908 55 0.337 
Latino 3738 11564 594 0.3232 
European (Non-
Finnish) 
18130 66734 2481 0.2717 
European 
(Finnish) 
1431 6614 143 0.2164 




7.4.2  Polycyclic aromatic hydrocarbons and phase II and phase 
III 
After subsequent synthesis of hydroxypyrene molecules, the molecules enter 
phase II. In phase II conjugation, hydroxypyrenes are conjugated to UDP-
glucuroniate (UDP- glucuronic acid, UDP-GA) for detoxification by UGT1A6 
(Figure 7.10) (Elovaara et al. 2007) and potentially UGT1A1 (Abnet et al.2007). 
Further research is recommended to validate whether pyrene is glucuronidated 
by UGT1A1. Furthermore, it would be interesting to reveal if pyrene molecules 




Figure 7.10: Phase II conjugation of 3-OH-benzo(α)pyrene. The molecular strucutre 
of 3-OH-Benzo(α)pyrene glucuronide has been adopted from (James et al. 2001). 
 
It is thought to be believed that hydroxypyrene glucuronides are transported by 
a ABC transporter but, there is a lack of evidence. Järvinen et al. (2017) 
reported that hydroxypyrene glucuronides can be transported by MRP4. Thus 
further research is recommended to validate the finding. Additionally, other 
research could explore if hydroxypyrene glucuronides are transported by any 
other ABC transporters.  
 
 
7.4.3 Polycyclic aromatic hydrocarbons and disease 
As discussed in Section 2.4.3, clotrimazole can suppress glucuronidation 
activity of hydroxypyrene for detoxification. The toxicological effects of pyrene 
molecules in humans remains for elucidation (Drukteinis et al. 2005; Sharma et 
al. 2008; Tarantini et al. 2011), only presenting in vitro data. But, murine model 




molecules on murines. A study conducted by Uno et al. (2004), reported in 
CYP1A1-/- mice, the presence of BaP molecules could produce BaP-DNA 
adducts alongside with bone marrow depression. Therefore, in individuals with 
reduced CYP1A1 expression BaP-DNA adducts could be formed which may 
lead to the development of disease. A later study conducted by Ribière et al. 
(2016) reported that if PAHs enter the body orally in the murine models used, 
intestinal inflammation is developed. Furthermore the faecal microbiota was 
also altered for instance, Bacteroidales species have been reported to be 
decreased. Therefore, if BaPs are orally entered into the body, inflammation 
and alterations to gut, mucous, and microbiota which could lead to other 
potential complications.  
 
7.5 Conclusion   
Pollution evidently poses a risk to human health, potentially more so in 
individuals with reduced gene expression that affects the detoxification 
pathway. The consumption of overcooked meats including fish, can lead to the 
development of PhIP-DNA adducts particularly in individuals with the 
UGT1A1*28 variant. Subsequently, the presence of the adducts can induce 
mutagenic effects which can contribute to colorectal cancer development, 
influenced by diet. The association of nicotine and disease is unclear and 
requires elucidation but, it is thought that nicotine my induce carcinogenic 
effects. Polycyclic aromatic hydrocarbons can also influence disease 
development. For instance, people who work with burning organic materials 
have an increased risk of developing lung cancer compared to those who do not 
burn organic matter (Bootdee and Chantara 2014; Juntarawijit  and Juntarawijit 
2017). The accumulation of polycyclic aromatic hydrocarbons in the lungs as a 
result of inhalation, polycyclic aromatic hydrocarbons could lead to DNA 

































Glucose is a versatile molecule that is utilised by different molecular pathways 
(Figure 8.1), particularly for the synthesis of uridine-diphosphate (UDP)-
glucuronate (glucuronic acid, UDP-GA). UDP-GA synthesis occurs via the 
uronic acid pathway (Figure 8.1), in the liver. Upon synthesis of UDPG-GA, the 
molecule is subsequently conjugated to xenobiotics and endogenous molecules 
(Esienberg et al. 1955; Horecker  and Hiatt 1958; Oya 1961; Inoue et al. 1969), 
producing glucuronides. Even if there is a disruption in glucose concentrations 
in the blood, glucose is still available. In hypoglycaemic conditions glucose is 
still produced from glycogen to glucose (glycogenolysis) (Mutel et al. 2011; 
Kuhre et al. 2015; Pedersen et al. 2018) (Figure 8.1), upon the stimulation of 
glucagon secreted by the pancreas. Conversely, in hyperglycaemic condition 
glucose is present in large concentrations (Rahmoune et al. 2005; Seo et al. 
2008; Pirola et al. 2011; Alam et al. 2014; Rahn et al. 2018), which can be 
synthesised to UDP-GA. Evidently, glucuronidation is the major conjugation 
process for phase II conjugation (Woelflingseder et al. 2019). Abnormalities in 
glucuronide specie production could lead to the development of glucuronide 
spectrums under abnormal conditions. Thus, the glucuronide spectrum may 
therefore, reflect all glucuronides produced associated with an abnormality in 
the detoxification pathway and disease. Thus, the glucuronide spectrum could 
be used in the application of disease diagnostics and prognostics. 
 
The application of glucuronide spectrums for disease diagnostics and 
prognostics could distinguish between disease causation (genetics or lifestyle 
factors). Additionally, the spectrum could be used to monitor disease severity by 
determining the production of glucuronide species and concentrations overtime. 
This is due to if disease severity increases, the production of glucuronide 
species may correlate to disease severity. Therefore, the aim of this review is to 
explore the concept of using glucuronide species to reveal a glucuronide 





























Figure 8.1: Glucose utilisation by different molecular pathways. Arrows pointing away from glucose shows glucose utilisation by a 
molecular pathway. Arrows pointing to glucose show glucose synthesis by a molecular pathway. In the Krebs cycle (citrate cycle) glucose can 
be synthesised and used as the starting molecule for the cycle. Gluconeogenesis converts pyruvate to glucose. Glycolysis produces pyruvate 
from glucose. The uronic acid pathway uses glucose to synthesise UDP-glucuronic acid. Glycogenolysis converts glycogen to glucose.
130 
 
8.1.1 Colorectal cancer 
The application of glucuronide spectrums to colorectal cancer (CRC) could be 
used to determine disease prognostics. Glucuronidation enzymes are not only 
expressed in the liver but, they are also expressed in the intestinal-colorectal 
region (Table 8.1). Thus, the expression patterns of the different uridine-
diphosphate glucuronosyltransferases (UGTs) may be altered. For instance, in 
CRC, UGT2B15 and UGT2B17 are down regulated (Guo et al. 2017; Shi et al. 
2018), as opposed to UGT1A1 and UGT1A10 which are up-regulated (Bélanger 
et al. 2010; Wang et al. 2013). The differences in gene expression, may 
produce different glucuronide species which could be used to construct a 
glucuronide spectrum.  
 
Table 8.1: Expression patterns of UGTs in the intestinal-colorectal region 
 
UGT Expression location  Reference 
UGT1A1 Small intestine (Fujiwara et al. 2012) 
UGT1A4 Duodenum  (Strassburg et al. 2000) 
UGT1A5 Small intestine and Colon (Finel et al. 2005) 
UGT1A6 Large and small intestine (Chen et al. 2005) 
UGT1A8 Colon (Mojarrabi et al. 1998) 
UGT1A10 Duodenum  (Strassburg et al. 2000) 
UGT2B15 Small intestine  
Colon 
(Strassburg et al. 2000) 
(Sun et al. 2011) 
UGT2B17 Small intestine 
Colon 
(Strassburg et al. 2000) 
(Ohno and Nakajin 2008) 
 
CRC can also develop from lifestyle factor such as dietary choices (Zhu et al. 
2013; Chen et al. 2015; Schwingshackl et al. 2017). Individuals who consume a 
large amount of meats are more at risk of developing CRC (Malfatti et al. 2006; 
Fede et al. 2009; Gu et al. 2011; Chiavarini et al. 2017). For instance, research 
has revealed that individuals who consume large amounts are more than likely 
to have an increased number of PhIP adducts present in the large and small 
intestine (Nicken et al. 2010; Jamin et al. 2013; Nicken et al. 2016; Durmus et 
al. 2019). This evidently demonstrates that PhIP adducts can be used as a 
predictor biomarker for CRCs. In relation to glucuronidation, the amount of PhIP 
and PhIP glucuronides present reflects the amount of meat consumed (Malfatti 
et al. 2006; Fede et al. 2009). Thus, PhIPs and PhIP glucuronides could be 




consumed. The presence of PhIPs and PhIP glucuronides and other molecules 
may cause increases UGT expression and therefore, increased glucuronide 
production occurs. Subsequently, increasing gusA expression in the gus operon 
system in Escherichia coli (E. coli). 
 
The microbiome in the colorectal region is affected by the presence of CRC 
(Bronowski et al. 2008). This is because studies have reported that E. coli B2 
phylotype strains, colonising around the cancer (Bronowski et al. 2008; 
Martinez-Medina et al. 2009; Prorok-Hamon et al. 2013; Mannion et al. 2016). 
Additionally, gusA expression is overexpressed in CRC (Gloux et al. 2010; 
Roberts et al. 2013; Gloux and Mondoloni 2016; Chen et al. 2017), due to the 
up-regulation of UGTs such as UGT1A5 (Wang et al. 2013) and UGT1A7 (Chen 
et al. 2019). The presence of glucuronides produced by up-regulated UGT 
expression induces an up-regulation in gusA expression coding for GusA (β-
glucuronidase) to cleave glucuronides. Therefore, the application of a 
glucuronide spectrum could be used for CRC diagnostics. Furthermore, the 
glucuronide spectrum could be used to monitor disease severity overtime, 
based on the glucuronide species and concentrations produced. 
 
8.1.2 Type 2 Diabetes mellitus  
In Type 2 Diabetes Mellitus (T2DM) increased glucose concentrations is 
present varying from 5.6 to 6.9mmol/L for prediabetes (intermediate 
hyperglycaemia, IH) and 7mmol/L for T2DM. The increased concentrations of 
glucose can therefore be utilised by the uronic acid pathway (Figure 8.1) for 
UDP-GA synthesis (Eisenberg et al. 1958; Winegrad and Shaw 1964), for 
phase II glucuronidation. Due to the increased presence glucose concentrations 
an array of glucuronide species could be produced that are linked with T2DM. 
 
In phase II the expression of several UGTs have been reported to be altered. 
UGT2B7 has been reported to have reduced expression in the presence of  
mycophenolic acid (Dostalek et al. 2011). Additionally, the expression of 
UGT2B1 expression has been reported to be reduced. In one study, UGT2B1 




L. extracts to determine expression activity (Chang et al. 2018). Conversely, the 
expression of UGT1A1, UGT1A6 and UGT1A7 is increased (Xie et al. 2013). 
Therefore, there could be a diverse range of glucuronide species that could be 
used to construct a glucuronide spectrum due to the increased UGT1A 
expression and increased concentrations of glucose.  
 
There are other complications that have been associated with T2DM leading to 
the development of other diseases and conditions. For instance, CRC (Levi et 
al. 2002), diabetic neuropathy (Sharma et al. 2002) and cardiovascular disease 
(Gæde et al. 2003). Individuals with T2DM have a decreased risk of prostate 
cancer as a result of reduced insulin production. Insulin may promote prostate 
cancer development (Hammarsten et al. 2010; Janghorbani et al. 2012; Tseng 
2014; Valentino et al. 2017; Kachhawa et al. 2018), by regulating CYP2E1 
expression. However, prostate cancer may still occur and could be determined 
by measuring prostate specific antigen (PSA) concentrations (Catalona et al. 
2000; Thompson et al. 2004; Ulmert et al. 2008). Therefore, the use of 
glucuronide spectrums could be used to monitor disease severity by revealing 
whether glucuronides that are produced reflect disease severity. Since 
determining blood glucose concentrations only reveal the presence of IH or 
T2DM only. 
 
8.1.3 Parkinson’s disease 
CYP2D6 encoded by CYP2D6 is a cytochrome p450 (CYP450) which belongs 
to phase I of the detoxification pathway. CYP2D6 is not only involved in phase I 
detoxification of xenobiotics but, it is involved with synthesising dopamine (DA) 
(Hiroi et al. 1998). The common pathway for dopamine synthesis utilises 
phenylalanine as a precursor molecule. Alternatively, DA can be synthesised 
from tyramine  by a hydroxylation reaction catalysed by CYP2D6, reported in a 
limited number of studies (Figure 8.2) (Hiroi et al. 1998; Zhu et al. 2005; 
Candiotti et al. 2009; Bromek et al. 2011). However, the synthesis of dopamine 





Figure 8.2: Hydroxylation of tyramine to dopamine  
 
CYP2D6*4 is a polymorphic variant of CYP2D6 with a reduced function as 
discussed (Section 4.1.1) and commonly associated with the European 
population (Table 4.2). One of the molecular characteristics in Parkinson’s 
disease (PD) is reduced dopamine production, due to the degradation of 
dopaminergic neurones (Cilla et al. 2010; Gröger et al. 2014; Kawashima et al. 
2018). However, it appears that an elucidation is not made between reduced 
dopamine and CYP2D6*4 in PD. In despite of CYP2D6*4 has been associated 
with PD (Harhangi et al. 2001; Santt et al. 2004; Singh et al. 2008; Lu et al. 
2013; Aslam et al. 2017). Therefore, further work is recommended to explore 
whether there is an association between CYP2D6*4 and DA synthesis in PD. 
Furthermore, the association of glucuronidation activity in PD is unclear. 
However, Landolfi et al. (2017) explored glucuronidation of bisphenol A in PD 
and concluded, glucuronidation activity is reduced. Thus, further exploration is 
required to understand how phase II is affected in PD.  
 
There are genetic tests which screen for a number of gene polymorphisms that 
can determine the onset of PD. Genetic tests can screen for the following genes 
and variants including : LRRK2 (G2019S) (Illarioshkin et al. 2007), PARK7 
(DJ1; early onset, Leu166Pro) (van Duijn et al. 2001), PINK1 (G411S) 
(Narendra et al. 2010), PRKN (PRK2) (exon deletion between 3 to 7, early 
onset) (Wu et al. 2005), and SNCA (G51D) (Kiely et al. 2013). Clearly, these 
criteria for genetic testing can complicate prognosis of PD. Instead, if there are 
glucuronide spectrums and glucuronide abnormalities, the spectrum could be 
used in the prognosis and diagnosis of PD. This is because if one of these gene 




8.1.4 Breast cancer 
The aid of a glucuronide spectrum for breast cancer prognostics would be 
beneficial. This is because females who carry BRCA1 and BRCA2 are at risk of 
breast cancer however, they may not necessarily develop breast cancer (Ayub 
et al. 2013). Therefore, the application of a glucuronide spectrum can be used 
to determine the presence of the cancer. Another molecular characteristic of 
breast cancer is increased oestrogen concentrations (Schairer et al. 2000; 
Kaaks et al. 2005). Thus, there is a possibility that oestrogen glucuronides are 
produced, along with other glucuronides. However, increased oestrogen can be 
influenced by other factors such as the contraceptive pill.  
 
The contraceptive pill is administered to prevent ovulation, which may contains 
oestrogen. Thus, when an individual uses the contraceptive pill, oestrogen 
concentrations increase (Lehtovirta et al. 1974; Briggs and Briggs 1977; Elliot et 
al. 1980). Even though there could be genetic predispositions, the 
predispositions may not necessarily cause breast cancer (Wiseman 2010). 
However, disruptions to the balance of oestrogen concentrations, increases the 
risk of breast cancer. Kumle et al. (2002) conducted a population study with 
100,000 women from Norway and 96,0000 from Sweden. The study reported 
that women on the study who used contraceptive pills had a 30% increased 
chance of breast cancer. A later study, Morch et al (2017), conducted a cohort 
study (1.79 million participants) and concluded that the use of the contraceptive 
pill increases the risk of breast cancer, compared to women who do not use the 
contraceptive pill. However, it appears there is not any evidence to contradict 
that contraception pills influence breast cancer development. Thus, lifestyle 
factors also contribute to the development of breast cancer.  
 
UGT2B15 encoding for the UGT21B5 protein is one of the phase II 
glucuronidation enzymes of the detoxification pathway. UGT2B15 has been 
reported to glucuronidate endogenous molecules such as oestrogen (Harrington 
et al. 2006) and testosterone (Strahm et al. 2013). In breast cancers, UGT2B15 
expression is up-regulated which may be due to increased oestrogen 




Lorca et al. 2015). Therefore, the presence of oestrogen glucuronides could be 
detected in patient samples with breast cancer, along with other potential 
glucuronides associated with breast cancer.  
 
 
8.1.5 Prostate cancer 
Prostate cancer is another hormone driven cancer that is influenced by 
testosterone concentrations (Koo and Shim 2010; San Francisco et al. 2014; 
Claps et al. 2018). Testosterone influences the expression of UGT2B15 
(Strahm et al 2013) and UGT2B17 (Basit et al. 2018). Increased testosterone 
up-regulates UGT2B15 and UGT2B17 expression and thereby, testosterone 
glucuronides are likely to be produced in prostate cancer, along with other 
possible glucuronides. Additionally, prostate cancer also alters phase I of the 
detoxification pathway.  
 
CYP450 expression in prostate cancers has been observed to be altered, 
particularly CYP3A5. CYP3A5 has affinity to testosterone to hydroxylate 
testosterone for phase II glucuronidation (Yamori et al. 2004; Leskelä et al. 
2007). In prostate cancer, the expression of CYP3A5 has been reported to be 
absent (Leskelä et al. 2007), down-regulated (Moilanen et al. 2007) or 
overexpressed (Jiang et al. 2015). These conflicting findings may account for 
the explanation that CYP3A5 expression may vary depending upon the severity 
of the cancer. Additionally, the concentrations of testosterone can also influence 
CYP3A5 expression. Therefore, this may contribute to glucuronide differences 
contributing to a glucuronide spectrum. 
 
ABC transporter expression is altered, causing an alteration in the fate of a 
molecule. ABCB1 is one of the ABC transporter that has gained attention, due 
to the overexpression of the ABCB1 gene (Reed et al. 2010; Zhu et al. 2013; 
Lombard et al. 2017; Nanayakkara et al. 2018). The overexpression of ABCB1 
consequently leads to the excretion of medicinal drugs used for cancer 
treatment causing resistance (Krech et al. 2012; Vallo et al. 2015; Liao et al. 




that can be detected in prostate cancer. However, the expression of ABCC4 in 
prostate cancer is reduced (Peraldo-Neia et al. 2011; Montani et al. 2013; Li et 
al. 2017; Orellana-Serradell et al. 2019). Testosterone is a substrate of the 
ABCC4 transporter and due to the reduced expression of the ABCC4 gene, 
testosterone accumulates in the prostate. Subsequently, the accumulation of 
testosterone can promote prostate cancer development. Thereby, testosterone 
glucuronides are likely to be present. 
 
Currently, prostate cancer is diagnosed by measuring PSA concentrations, 
taking biopsies and MRI scans. However, MRI scans may not detect the cancer 
and a biopsy sample may not contain the cancer or multiple biopsies are 
required. The issue with determining PSA concentrations is that PSA can also 
be detected in prostatitis (Azab et al. 2012; Lokant and Naz 2014; Li et al. 2017; 
Lee et al. 2019). Clearly, there are difficulties in current prostate cancer tests 
and the application of a glucuronide could be used alongside current practices 
to determine the presence of the cancer.  
 
8.1.6 Liver cancer 
The liver is the predominant location for molecule detoxification (Girad et al. 
2005; Mueller et al. 2010; Bartl et al. 2015; Hu et al. 2018). A disease that 
affects the liver could alter the detoxification process of molecules. The 
implications of liver cancer on the detoxification pathway provide conflicting 
reports. Ye et al. (2014) reported glucuronidation activity is reduced in liver 
cancers whilst, a later study reported glucuronidation catalysed by UGT1A9 is 
increased (Ge et al. 2019). In other phases such as phase I, multiple CYP450s 
are down-regulated: CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2E1 and 
CYP3A4 (Ren et al. 2018). The down-regulation of CYP2C8 is thought to 
influence survival time of liver cancer after a hepatectomy (Wang et al. 2018). 
Further research is recommended to elucidate the connection between the 
expression of CYP2C8 and survival time (Liu et al. 2019). Additionally, 
glucuronidation in phase II is altered. Since glucuronidation occurs in the liver 
potentially, there could be an array of glucuronides produced that may reflect 




detoxification, an array of glucuronides could be produced that reflects liver 
cancer.       
 
Currently, liver cancers can be diagnosed by one of two ways, ultrasound scans 
(Cottone et al. 1983) or determining alpha-fetoprotein (AFP) concentrations 
(Chen et al. 1984). AFP protein is produced by the AFP gene and highly 
produced in the foetal liver. In the human adults, normal AFP concentrations is 
<10 ng/mL (Jeon et al. 2017).  The issue with ultrasound is that the cancer may 
not be revealed from the scan. Determining AFP concentrations is an issue 
because AFP has been found to be associated with other cancers such as 
testicular (Paffenholz et al. 2018) and ovarian (Aldrink et al. 2018). Therefore, 
the application of glucuronide spectrums to determining the presence of liver 
cancer can be used alongside other diagnostic practices for this disease. 
8.2 Results 
A total number of 300 papers were collected from Scopus (n=62), Web of 
Science (n=48), NCBI PubMed (n=123) and Google Scholar (manual search) 
(n=67). After reviewing the papers for glucuronides associated to a disease 
(refer to Section 2.3), a total of three papers were eligible for colorectal cancer. 
Two papers were found reporting glucuronides associated to Type 2 Diabetes 
Mellitus (Table 8.3). Six papers were found to report glucuronides associated 
with prostate cancer. Four papers reported glucuronides associated with breast 
cancer (Table 8.5). Only two papers revealed glucuronides associated to 
colorectal cancer and genetics (Table 8.2) However, there were not any papers 
reporting an association of glucuronides for liver cancer and Parkinson’s 
disease.    
 
8.2.1 Colorectal cancer              
8.2.1.1 Colorectal cancer, lifestyle and glucuronides 
In the one study that was eligible after screening for CRC causation by lifestyle 
only one glucuronide was detectable, ethyl glucuronide. The study explored 
metabolites associated with a diet and the metabolite diet-disease relationship. 




using two different screening approaches; ultra-high-performance liquid-phase 
chromatography with tandem mass spectrometry (UPLC/MS) and gas 
chromatography–mass spectrometry (GC/MS) (Guertin et al. 2014). The ethyl 
glucuronide only shows that alcohol consumption may contribute to the cause of 
CRC development but, may not be a glucuronide specifically associated to 
CRC. Alternatively, ethyl glucuronide was detected in the patients who may 
have consumed alcohol.  
 
8.2.1.2 Colorectal cancer, genetics and glucuronides 
Once the inclusion and exclusion criteria were followed two papers reported 





































































































































































8.2.2 Type 2 Diabetes Mellitus  
After examining the two papers related to T2DM causation by lifestyle all 
glucuronides have been reported (Table 8.3). This potential spectrum only 
presents three detectable glucuronides associated with T2DM and lifestyle 
factors. However, there could be more glucuronides which remains to be 




Table 8.3: Glucuronides reported that are associated with T2DM caused by 



































P<0.05 (Li et al. 
2017) 
 
In one of the two studies referenced in Table 8.3 the ethnicity has been reported 
from the participants involved in the study. Whereas, the other study did not 
report ethnicity of the participants. Li et al. (2017) reported the participants in 
the study the ethnicities to be: African-American, Hispanic, Non-Hispanic and 
Mexican. However, the authors did not associate glucuronide production to a 
particular ethnicity. Thus, this suggests that androstanediol glucuronide (ADT-
G) is present in all ethnicities. Additionally, the number of people reported for 
each ethnicity is not reported in the study. Conversely, Zhao et al. (2017) did 
not report any ethnicities in the study. Therefore, further work is recommended 
to associate whether glucuronides produced are the same in different ethnicities 
in the presence of T2DM or whether, there could be a variation in glucuronide 
production in different ethnicities. 
 
 
8.2.3 Parkinson ’s disease 
After following the protocol outlined in Section 2.3, using the inclusion and 
exclusion criteria, no eligible studies has been identified. Therefore, further work 
is necessary in the form of metabolomic studies to identify potential 





8.2.4 Prostate cancer 
8.2.4.1 Prostate cancer, genetics and glucuronides  
In Table 8.4 below presents all potential glucuronides that could be detected to 
aid in the diagnosis of prostate cancer, caused by genetics. This potential 
spectrum could be used alongside with other diagnosis methods to confirm the 
presence of prostate cancer. Multiple studies reported in Table 8.4 report the 
same three glucuronides androsterone glucuronide (ADT-glucuronide), 
androstane-3α,l7β-diol-3-glucuronide (3α-diol-3G) and  androstane-3α,17β-diol-
17-glucuronide (3α-diol-17G) for prostate cancer. Therefore, this validates that 































Unfortunately, none of the studies, excluding one of the studies did not 
associate glucuronide production and ethnicity. Hsing et al. (2001), reported 5α-
androstane-3α,17β-diol glucuronide in an Asian population. Thus, this suggests 
that glucuronide production may not vary between different ethnicities. 
However, multi-ethnic studies are necessary to elucidate the possibility of any 
variation in glucuronide production in a disease within different ethnicities.  
 
8.2.4.2 Prostate cancer, lifestyle and glucuronides   
The one study dated 2009 that matched all inclusion criteria for this systematic 
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(height, weight, smoking, physical activity and diet, including alcohol). 
Androstanediol glucuronide (A-diol-g) measured by a radio-immunoassay (RIA). 
The study concluded that smoking does not alter glucuronide concentrations 
(P<0.0001), physical activity did not alter glucuronide concentrations and 
alcohol consumption was not reported and the effect it had on A-diol-g 
production (Suzuki et al. 2009). Therefore, it is evident that further and up to 
date research is necessary to elucidate whether there are other glucuronides 
associated with prostate cancer and lifestyle. Alternatively, whether there are 
other potential lifestyle factors such as nightshift work alert glucuronide 
concentrations.  
 
8.2.5 Breast cancer, genetics and glucuronides  
The two applicable studies presented in Table 7.5 after analysing, only two 
glucuronides have been found to be produced in breast cancers. However, 
















































































































After a further analysis of the papers, a search was taken into each of the 
studies referenced in Table 8.5, to explore whether ethnicities have been 
reported. Johnson et al. (2012), had patients of white ethnicity from the United 
Kingdom. However, Johnson et al. (2016) did not report any ethnicities. 
Romero-Lorca et al. (2015) did not report ethnicities. Therefore, providing 
evidence that multi-ethnic studies are recommended which elucidates whether 
glucuronide species produced are different within ethnic backgrounds.  
 
8.2.6 Liver cancer and glucuronides  
Unfortunately, after screening there were not any glucuronides that have been 
associated with liver cancer influenced by genetics or lifestyle factors. It is 
known  that the liver functions to detoxify the body from endogenous (Bosma et 
al. 1995; Ando et al. 1998; Hong et al. 2004; Lin et al. 2006; Hirata et al. 2010; 
Ekström et al. 2012) and xenobiotic molecules (Iyer et al. 2002; Ortega et al. 
2007; Larson and Richards 2009; Buchard et al. 2012; Raza et al. 2015; 
Kuzikov et al. 2019). Therefore, there could be an alteration in glucuronide 
production due to the presence of cancer. However, there could be difficulties in 
identifying potential glucuronides associated with liver cancer. This could 
potentially be due to the different types of liver cancer and thereby, 




potential glucuronides produced associated with different types of liver cancer 
(see Discussion Section 8.3.5).  
 
8.3 Discussion and conclusion 
The glucuronide spectrum consists of different glucuronide species that are 
produced from glucuronidation in phase II of the detoxification pathway. 
Abnormalities in the detoxification pathway may alter the production of 
glucuronide species which can be used to construct glucuronide spectrums. In 
previous work, genotyping was used to identify polymorphisms associated to a 
disease (Zwemmer et al. 2004; Hsiao et al. 2008; Jung et al. 2012; Jakobsen et 
al. 2014; Takeuchi et al. 2017), which is insufficient to determine a disease. This 
is because the presence of a variant may not be the cause of disease. 
Alternatively, determining a drug which an individual may or may not use 
(Bunten et al. 2011; Gadel et al. 2013; Kharasch et al. 2015; Burgess et al. 
2017). This is because even though a gene variant is present the disease may 
not be present. Thus, by having a glucuronide spectrum can confirm the 
presence of a disease and could be used to monitor disease overtime.   
 
The aim of this review was to construct a glucuronide spectrum using 
glucuronides that have been reported in published research that are disease 
associated. The aim of this review has been achieved. Glucuronide spectrums 
have been successfully constructed that reflects all known glucuronides 
associated to a disease. The glucuronide spectrums that reflect glucuronides 
produced in the presence of genetic variants with genetics could be used 
alongside genetic tests to determine gene variants and disease. This is 
because these results show glucuronide synthesis associated to a disease, with 
the presence of gene polymorphisms and lifestyle (see Results section).  
 
8.3.1 Type 2 Diabetes Mellitus  
Both 2-phenylethanol glucuronide and deoxycholic acid 3-glucuronide are 
naturally occurring glucuronides which are synthesised from 2-phenylethanol 
(Dong et al. 2015) and deoxycholic acid (Perreault et al. 2018), respectively. 




T2DM (Sun et al. 2014; Zhao et al. 2015; Zhao et al. 2017). Therefore, this 
suggests that molecular pathways such as the phenylethylamine pathway and 
the Ehrlich pathway (2-phenylethanol synthesis) and deoxycholic acid synthesis 
pathway could be upregulated (Zhao et al. 2017). Alternatively, the UGTs which 
glucuronidate deoxycholic acid and 2-phenylethanol could be upregulated.  
 
Androstanediol (ADT) is a metabolite of dihydrotestosterone (DHT), which is a 
neurosteroid with anticonvulsant activities. This is because androstanediol can 
bind to GABA receptors in the brain (Frye et al. 1996; Imamura and Prasad 
1998; Frye et al. 2001; Reddy 2004; Kaminski et al. 2006; Reddy and Jian 
2010; Krishnan et al. 2012; Shahrzad and Nasser 2015; Chuang et al. 2019). 
DHT is an intermediate molecule for testosterone synthesis and since ADT is a 
metabolite of DHT low concentrations of ADT-G is expected in T2DM (Joyce et 
al. 2016). 2-phenylethanol glucuronide was also detected in one of the excluded 
studies which used male Wistar rats, modelling T2DM. Sample collected were 
urine and blood samples which were analysed by UPLC/MS (Sun et al 2014).  
 
Furthermore, glucuronides have been reported that are associated to T2DM 
and lifestyle factors in a murine study. In a excluded study that did not meet the 
inclusion criteria. Sun et al. (2014) reported that 2-phenyethanol glucuronide 
(P=0.02) is produced alongside with 6-hydroxy-5-methoxyindole glucuronide 
(P=0.03), in rats that were fed a high fat diet. Therefore, this contributes to the 
validation that 2-phenyethanol glucuronide is associated with T2DM. 
Furthermore once glucuronide spectrums for disease in humans have been 
revealed experimentally, glucuronide spectrums could be applied to disease 
diagnostics for animals.  
 
8.3.2 Colorectal cancer  
3αdiol G is a type of androstanediol glucuronide that can be detected in human 
samples (Morimoto et al. 1981; Moghissi et al. 1984; Lobo et al. 1987). 
Androstanediol glucuronide has also been detected in T2DM but, the specific 
type of androstanediol glucuronide detected in Li et al. (2017) was not 




name should be reported. However, there could as well be other glucuronides 
which may have not been reported but, yet could be detectable. This is because 
androstandediol is an umbrella term for the following specific androstanediol 
molecules: 3β-Etiocholanediol (5β-androstane-3β,17β-diol; etiocholane-3β,17β-
diol), 3α-Etiocholanediol (5β-androstane-3α,17β-diol; etiocholane-3α,17β-diol),  
3α-Androstanediol (5α-androstane-3α,17β-diol) and 3β-Androstanediol (5α-
androstane-3β,17β-diol). Therefore, these other molecules could also be 
potential biomarkers for CRC. Additionally, SN-38 glucuronide has been 
associated with colorectal cancer and glucuronides because even though it is a 
drug, it is still glucuronidated in the presence of UGT1A1*28 (Table 8.3).  
 
8.3.3 Prostate cancer  
In the present review, several glucuronides have been reported that are 
associated with prostate cancer influenced by genetics (Table 7.5). ADT-G 
derives from androsterone by which ADT is a metabolite of dihydrotestosterone. 
(DHT) (Pirog and Collins 1999; Bloch et al. 2006). 3α-diol-3G has also been 
found to be glucuronides associated with prostate cancer and genetics, which 
has been detected in multiple studies in Table 7.5, showing validation and 
evidence that 3α-diol-3G is associated with prostate cancer. Androstenadiols 
are also metabolites of DHT (Moghissi et al. 1984; Toscano and Horton 1987). 
Currently, ADT-glucuronide, 3α-diol-3G, 3α-diol-17G and 5α-androstane-
3α,17β-diol glucuronide are the only known glucuronides that are associated 
with prostate cancer. But, there could be other glucuronides which are 
associated with prostate cancer but have not yet been detected. Thus, the 
detection of the known glucuronides in this case suggests that hormone 
concentrations are increased. Hsing et al. (2001) reported 3α-diol-17G in an 
Asian population, but the other studies did not report ethnicities. Therefore, 
multi-ethnic studies are recommended to reveal glucuronide spectrums for a 
disease in different ethnicities. This is because, the glucuronide species 
produced may have a variation in different ethnicities and thus, there could be a 





8.3.4 Breast cancer 
Oestrone-3-glucuronide (E1G) is synthesised from oestrone, a type of 
oestrogen (Strassburg et al. 2002; O’Connor et al. 2003; Thibaudeau et al. 
2006). E1G is the only known glucuronide that is associated with breast cancer 
however, there could be other associated glucuronides which may be 
associated with breast cancer.  Oestrone has functional roles in influencing the 
onset of the reproductive menstrual cycle alongside with oestradiol (Sipavičiené 
et al. 2015). In breast cancers, the concentrations of oestrone have been 
reported to increase in premenopausal woman (Miyoshi et al. 2003; Adly et al. 
2006; Woolcott et al. 2010; Falk et al. 2013; Endogenous Hormones and Breast 
Cancer Collaborative Group 2015; Goedert et al. 2018), hence E1G has been 
detected. However, oestradiol glucuronides were not detected, despite of 
oestradiol concentrations have been reported to be increased in 
postmenopausal women, increasing the risk of breast cancer (Holmberg et al. 
2001; Saito et al. 2004; Tamimi et al. 2007; Potter et al. 2009; Walker et al. 
2011; Shoemaker et al. 2014; Sampson et al. 2017). Therefore, further 
metabolic/metabolite biomarker studies are recommended, to show other 
potential metabolites associated with breast cancer.  
 
Tamoxifen is a hormone-therapy based drug used for the treatment of breast 
cancer (Frasor et al. 2006; Cajol et al. 2010; Cuzick et al. 2014; Neven et al. 
2018). The mechanism of tamoxifen is by binding to oestrogen receptors (ERs) 
inducing conformational changes (Gorodeski et al. 1992; Webb et al. 1995; 
Shiau et al. 1998). The binding of tamoxifen to oestrogen receptors prevents 
further cancer development, preventing oestrogen from binding to oestrogen 
receptors. Tamoxifen has been demonstrated to undergo glucuronidation by 
UGT1A4 (Sun et al. 2004) and UGT2B17 (Romer-Lorca et al 2015). In the 
presence of gene variants, tamoxifen can still be glucuronidated as 
demonstrated in the results in Table 7.6.  
 
8.3.5 Liver cancer 
After examining all collected papers (n=87), there were not any papers that 




The liver is responsible for the detoxification of xenobiotics and endogenous 
molecules. This is due to that the research available has not discussed 
glucuronide synthesis and liver cancer. This may be due to the fact that liver 
cancer can appear as primary liver cancer including: hepatocellular carcinoma 
(HCC) (Naugler et al. 2007), cholanigocarcinoma (bile duct cancer) (Inaba et al. 
2007), liver  angiosarcoma (Averbukh et al. 2018) and hepatoblastoma (Pham 
et al. 2015) or secondary liver cancer caused by other cancers that have 
metastasised such as colorectal cancer metastasis to the liver (Fong et al. 
1999; Choti et al. 2002; Gupta et al. 2005; Zeng et al. 2008; Halama et al. 2011; 
Landreau et al. 2014; Moro et al. 2018). Exploring glucuronides from liver 
cancers could not only be used to determine the presence of a type of liver 
cancer but, the glucuronide species to construct a glucuronide spectrum, may 
be able to determine the difference between primary and secondary liver 
cancer.  
 
8.36 Parkinson’s disease 
After reviewing all papers for PD (n=16), there were not any papers of 
glucuronides reported that are linked with the disease. Therefore, further 
research in the metabolomics of PD to establish all potential metabolites 
including glucuronides that are associated with PD. In despite of CYP2D6*4 has 
been found to have a link with PD as discussed in Section 7.1.3 Once the 
metabolites have been revealed from metabolomic studies, then potential 
glucuronide spectrums for PD could be revealed.  
 
8.4 Conclusion 
The aim of the review was to explore the potential application of glucuronides 
for disease prognostics. The results presented in this review demonstrate that 
there are glucuronide spectrums associated with diseases. In colorectal cancer, 
three glucuronides have been associated with genetic predispositions of 
colorectal cancer (Table 8.3): 5α-androstane-3α, 17β-diol glucuronide and SN-
38 glucuronide.  In Type 2 Diabetes Mellitus, three glucuronides have been 
found to have an association with diet. In prostate cancer three glucuronides 




UGT2B15 null deletion genotype, SRD5A1 and SRD5A2 (see Table 8.4 for 
polymorphisms).  Androsterone glucuronide is the only glucuronide that has 
been associated with prostate cancer and lifestyle factors. Breast cancer 
influenced by genetics has three glucuronides associated to the disease 
estrone-3-glucuronide (CYP3A rs10273424 and CYP3A7*1C) , tamoxifen-n-
glucuronide (UGT1A4: rs6755571 and rs2011425), and 4-OH tamoxifen-O-
glucuronide (UGT2B7: rs7439366). However, the link between glucuronide 
production and ethnicity is not fully elucidated. Therefore, multi-ethnic studies 
are recommended for future work. 
 
8.5 Strengths and limitations 
The strength of this review reveals that there are glucuronide spectrums 
diseases (see Results section), based on available published research which 
matched the inclusion criteria implemented in this review. Additionally, the 
concept of a glucuronide spectrum has not been discussed in previous 
research. To date, this is the first systematic review that has explored the 
concept of glucuronide spectrums associated to disease for prognosis. But, 
there are limitations that should be considered.  
 
The limitations to this review is that the concentrations of glucuronides have not 
been discussed in the ellegible studies in relation to a disease. Furthermore, the 
ellegible studies used in the review did not discuss or compare glucuronide 
concentrations in patients diagnosed with a disease and healthy controls. 
Additionally, it is evident that the glucuronides reported were not linked to a 
particular ethnicity. Therefore, ethnic studies and glucuronide concentrations 
are recommended, glucuronide concentrations may vary in a disease amongst 
































9.1 Summary of the thesis  
The aim of the thesis was to explore the potential application of glucuronides for 
disease prognosis. The aim of this chapter has been successfully achieved as it 
is evident within the results section of Chapter 8, with the revealing of different 
potential glucuronide spectrums, associated with a number  of different 
diseases. Several Chapters have been produced to discuss the implications of 
gene variants influencing the fate of different molecules when they are 
detoxified within the liver to achieve the implemented objectives of the research. 
Respectively, objectives 1 and 2 was to evaluate genetic and lifestyle factors 
that may affect the detoxification pathway, which has been achieved. Objective 
3 was to evaluate different human gene allele frequencies that is reported 
Chapters 3 to 7. Objective 4 was to reveal potential glucuronide spectrums 
reflecting objectives 1 and 2, which has been achieved in the results section of 
Chapter 8. Objective 5 was to postulate the potential clinical applications of the 
research has been discussed in Section 9.2 (see below). 
 
Chapter 3 discussed the implications of gene variants on the detoxification on 
medicinal drugs. In despite of medicinal drugs having a role for their  
therapeutic effects, medicinal drugs can cause adverse effects and interfere 
with the detoxification other molecules. For instance, clotrimazole is used for the 
anti-fungal properties against dermatological conditions such as thrush. 
However, clotrimazole interferes with the glucuronidation of polycyclic aromatic 
hydrocarbons (PAHs) (Das et al. 1986). Clotrimazole can also induce 
hepatotoxicity which could also disrupt the detoxification of other molecules and 
lead to the progression of other diseases such as cancers. However, further 
research is recommended to reveal how clotrimazole influences the 
detoxification of medicinal drugs and endogenous molecules.  
 
Chapter 4 discussed the detoxification of illicit drugs and how they are affected 
by genetic variation. For one example, In despite of methadone being used in 
opioid withdrawal programmes for the medicinal properties, methadone is an 
illicit drug. The use of methadone can also lead to addiction and prolonged use 




can be influenced by two gene variants, CYP2B6*6 (reduced expression) 
(Gadel et al. 2013) and CYP2D6*4 (non-functional) (Gough et al. 1990) Both 
variants could also contribute to methadone related deaths as a result of 
increased methadone molecules. Furthermore, drug-drug based interactions 
may also influence methadone related deaths, for example quinidine and 
methadone. Quinidine alters the fate of methadone by suppressing MDR1 
transport activity of methadone. Thus, individuals who take quinidine along with 
methadone, shows increased methadone concentrations and as a result this 
could also contribute to methadone related death (Kharasch et al. 2004; 
Kharasch et al. 2008).  
 
Food additives are used to improve the quality, taste, appearance, and shelf 
life. Before food additives are applied to food, they are rigorously tested and 
declared whether an additive is safe by the European Food Safety Authority 
(EFSA). However, in despite of testing food additives, they still pose as a risk to 
human health. For instance, as discussed in Section 4.1, individuals with 
phenylketonuria (PKU)  have a mutated phenylalanine hydroxylase (Gámez et 
al. 2000; Muntau et al. 2002). Thus, when phenylalanine concentrations are 
increased, phenylalanine is toxic. Increased phenylalanine can lead to seizures 
and other cognitive impairments (Martynyuk et al. 2007; Karimzadeh et al. 
2012; Danafar and Hamidi 2015), due to the consumption of aspartame 
containing foods.   
 
Endogenous molecules as discussed in Chapter 6, are naturally produced 
within the body (Mendelson et al. 1975; Chung and Allison 1979; Bowen et al. 
2011). However altered concentrations of endogenous molecules can be 
harmful. In hormone driven cancers such as prostate cancer, the cancer can be 
influenced by increased hormone concentrations (Stanbrough et al. 2006; 
Coward et al. 2009; Muller et al. 2012), by which abnormal concentrations 
induce abnormal cellular growth. Furthermore, mutations within the 
detoxification pathways such as the UGT2B17 deletion, increases testosterone 
concentrations. Furthermore, in other diseases such as Gilbert’s syndrome, 
increased bilirubin concentrations are present that leads to jaundice due to the 




2001). Additionally, individuals who have Gilbert’s syndrome cannot detoxify 
other molecules effectively such as PhIPs leading to a potential onset of 
colorectal cancer (CRC) (Girard et al. 2005; Chang et al. 2007).   
 
Xenobiotics, discussed in Chapter 7, can also influence the onset of disease 
through different molecular interactions. For instance, as discussed in Section 
6.1, PhIPs have the ability  to bind to DNA forming adducts (Ghoshal et al. 
1995; Dingley et al. 1999), that are carcinogenic contributing to colorectal 
cancer development. Xenobiotics can also interfere with the detoxification of 
other molecules. Ethanol can also be detoxified via glutathione (GSH) 
detoxification (Otis and Guidot 2010; Chitty et al. 2013; Chen et al. 2017), 
likewise for acetaminophen (APAP). Thus, while ethanol depletes GSH 
molecules in the liver, APAP is able to bind to molecules within the liver to 
promote hepatotoxicity.    
 
The main strength from the thesis is that the aim has been successfully 
achieved by revealing different glucuronide spectrums for a number of disease 
(Section 7.3). The newly revealed glucuronide spectrums also reveal whether a 
disease is influenced by genetics or lifestyle factors. Furthermore, if a disease is 
influenced by genetic factors, the glucuronide spectrum could help to identify 
what gene variants are present that influenced a disease as evident in Tables 
7.3, 7.5, and 7.6. Therefore, the application of glucuronides spectrums could be 
used for disease prognostics and diagnostics in the future.  
 
The major limitation to the thesis is that there is not experimental work, 
validating the theoretical results presented in the results section of Chapter 7. 
Without the theoretical results that show whether glucuronide spectrums existed 
or not, it appeared inappropriate to conduct laboratory work until theoretical 
results have been reported. However, the experimental work can be done for 





9.2 Future directions 
To develop the research further, the next step is to undertake laboratory work to 
validate the theoretical findings. The laboratory work will use human biological 
samples (blood and urine) from diagnosed patients, with a disease discussed in 
Chapter 7, who provide informed consent following the Data Protection Act 
2018. Once the samples have been received the blood samples will be 
centrifuged to obtain the different components of blood and stored in the fridge 
until analysis. Urine samples will also be stored in the fridge until analysis or 
frozen. Furthermore, healthy controls will also be invited to provide blood and 
urine samples. Sample analysis will include screening for glucuronide 
spectrums by matching patient and healthy control based on age, gender 
(Kutner et al. 2000; Vaidya et al. 2003; Frankfort et al. 2006; Baum et al. 2009; 
Chiu et al. 2011; Booth et al. 2014; Yeh et al. 2016; Karlin et al. 2018; Wang et 
al. 2019), and ethnicity. This is to reveal whether there are variations within a 
glucuronide spectrum between different ethnicities and between healthy people 
and people who have been diagnosed with a disease. The screening method to 
reveal glucuronide spectrums will use the UPLC-HRMS system. This is 
because UPLC-HRMS  is a common method for metabolomics studies 
(Nordström et al. 2006; Zelena et al. 2009; Syzmańska et al. 2011; Sun et al. 
2014; Li et al. 2016; Schoeman et al. 2018; Zhao et al. 2019). Once a 
glucuronide spectrum has been determined, the next step would be to 
determine the concentrations of each glucuronide specie. The purpose of 
determining glucuronide concentrations is to elucidate if a specific glucuronide 
is produced in increased or decreased concentrations.  Once, experimental 
data has been gained which reveals glucuronide spectrums (validating the 
results in the thesis and experimental repeats have been  performed, validating 
the initial experimental findings) and concentrations are determined then the 
application of glucuronide spectrums could be used alongside current practices 








9.3 Concluding remark 
Glucuronides are molecules that are produced in the liver by the detoxification 
pathway of different molecules. However, the detoxification pathway can be 
affected by genetics and lifestyle factors, altering the fate of a molecule. The 
aim of the thesis was to explore potential glucuronide spectra for different 
diseases caused by genetics and lifestyle factors. The aim of the thesis has 
been successfully achieved with revealing different glucuronide spectra for 
different diseases. Thus, the next step from this research is to conduct 
experimental work to reveal different glucuronide spectrums and to determine 
the concentrations of each glucuronide specie.  
 
 
